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Supplementary Note 
United Kingdom Household Longitudinal Study (UKHLS) 
United Kingdom Household Longitudinal Study (UKHLS): The United Kingdom Household Longitudinal 
Study, also known as Understanding Society (https://www.understandingsociety.ac.uk) is a longitudinal 
panel survey of 40,000 UK households (England, Scotland, Wales and Northern Ireland) representative of 
the UK population. Participants are surveyed annually since 2009 and contribute information relating to 
their socioeconomic circumstances, attitudes, and behaviours via a computer assisted interview. The study 
includes phenotypical data for a representative sample of participants for a wide range of social and 
economic indicators as well as a biological sample collection encompassing biometric, physiological, 
biochemical, and haematological measurements and self-reported medical history and medication use. The 
United Kingdom Household Longitudinal Study has been approved by the University of Essex Ethics 
Committee and informed consent was obtained from every participant. 
Lung function measurements were used from samples in England and Wales only where the electronic NDD 
Easy On-PC spirometer was used. For each participant the two highest FVC and FEV1 measurements are 
taken. Measurements were not taken from individuals who were pregnant, had abdominal or chest surgery or 
a heart attack in the last three months, had a detached retina or eye or ear surgery in the past 3 months, 
admitted to hospital with a heart complaint in the preceding month, had a resting pulse rate more than 120 
beats/minute, or currently taking medications for the treatment of Tuberculosis.  
10,484 UKHLS samples were genotyped using the Illumina Infinium HumanCoreExome (12v1-0) at the 
Wellcome Trust Sanger Institute, Hinxton, UK and genotypes were called using Illumina Genome Studio 
Gencall. Variants were mapped to NCBI build 37 (hg19) coordinates and strand was standardised 
(http://www.well.ox.ac.uk/~wrayner/strand/). Samples were excluded according to the following: call rate < 
98%, autosomal heterozygosity outliers (> 3 SD), sex discrepancy, duplicates established using identity by 
descent (IBD) PI_HAT > 0.9, ethnic outliers after combining with 1000 Genomes Project data and carrying 
out IBD and multidimensional scaling. Variants were excluded with Hardy-Weinberg equilibrium (HWE) p-
value < 1x10-4, call rate < 98% and poor genotype clustering values (< 0.4). Unrelated samples were 
determined by performing IBD and samples with PI_HAT > 0.2 were excluded resulting in 9,308 samples 
and 525,314 variants.  
Prior to phasing additional variant QC was performed; duplicates, monomorphics and singletons were 
excluded. Will Rayners script was used for comparing alleles and frequencies with the 1000 Genomes 
Project haplotypes (http://www.well.ox.ac.uk/~wrayner/tools/). Samples were phased using SHAPEIT 
v2.r778. A combined reference panel was used consisting of 1000 Genomes Project
1
 (27,449,245 variants 
and 1,092 samples), and UK10K
2
 (25,109,897 variants and 3,781 samples). For 1000 Genomes Project the 
haplotypes used were 1000 Genomes Project (1000G) haplotypes Phase I integrated variant set release 
(ALL.integrated_phase1_SHAPEIT_16-06-14.nosing) downloaded from the IMPUTEv2 website 
(http://mathgen.stats.ox.ac.uk/impute/impute_v2.1.0.html). For UK10K the haplotypes were prepared and 
described previously
2,3
. IMPUTEv2
4,5
 was used for imputation. Post imputation variant QC consisted of 
excluding variants with an IMPUTE info score < 0.4 and/or HWE p-value < 1x10
-4
.   
 
Studies contributing to analyses of COPD susceptibility and risk of exacerbation 
UK Biobank 
In UK Biobank, COPD status was defined based on spirometry with individuals with % predicted 
FEV1<80% and FEV1/FVC<0.7 (indicative of moderate to severe COPD
6
) selected as COPD cases. 
 Individuals with FEV1/FVC>0.7 and % predicted FEV1>80% were selected as controls (in UK BiLEVE, 
controls were selected from the high % predicted FEV1 group only and all had % predicted FEV1>107%).  
Individuals were defined as exacerbation cases is they were COPD cases, as defined above, and had any of 
the following ICD-10 codes, according to the Hospital Episodes Statistics (HES) in UK Biobank: from J40 
to J44 (excluding J43.0), J06.9, J13 to J16, J18 (excluding J18.2), J20.8, J20.9 or J22. Exacerbation controls 
were defined as COPD cases (as above) who were not exacerbation cases. 
Analyses were carried out using the score test, implemented in SNPTEST v2.5b4 
7
 assuming an additive 
genetic model of genotype dose. For never-smokers, sex, age, age
2
, height and the first 10 ancestry principal 
components were included as covariates. For heavy-smokers, pack years were included as an additional 
covariate. The results for never and heavy-smokers were then combined, using inverse variance weighted 
meta-analysis. Due to minor differences in the array and imputation, analyses were carried out separately in 
the stage 1 UK BiLEVE subset and the stage 2 subset of UK Biobank and results were meta-analysed 
(inverse variance weighted).  
deCODE COPD Study 
deCODE genetics have collected spirometry data through their own phenotyping efforts and through 
epidemiological studies and clinical services carried out by collaborating physicians. The available 
measurements were performed between 1977 and 2010. Quality controlled spirometry data without prior 
administration of an inhaled bronchodilator medication was available for 4,872 individuals with genotype 
information. Based on the latest spirometry result available for each individual, a COPD diagnosis was made 
if the GOLD 2 criteria was fulfilled (FEV1/FVC < 0.70 and FEV1 % of predicted < 80). This resulted in a 
group of 1,964 spirometrically defined COPD patients with age at spirometry > 40 years. Of those, 1,248 
were chip-typed and directly imputed; the remaining 716 were first or second degree relatives to chip typed 
individuals and had their genotypes inferred based on genealogy 
8
. 1,236 were GOLD 2, 590 were GOLD 3 
and 138 were GOLD 4 patients. Based on the available information on smoking status, subgroups of ever-
smokers (1,015 chip typed, 535 relatives) and never-smokers (87, all chip typed) were defined.  
Single variant association testing was performed using logistic regression, adjusting for sex, age and county, 
as previously described 
9
. Genotypes were familially imputed into close relatives of chip typed individuals, 
achieving sample sizes of 1,964 for all COPD, 1,550 COPD smokers and 87 COPD non-smokers. 
Population controls (142,262) were used for analysis of the entire COPD cohort, but for the smoker and non-
smoker subsets, selected control groups of 7,468 and 449 individuals, respectively, matched on sex, age, 
smoking status and genotyping status were used. 
Familially imputed genotypes are not applicable to genetic risk score analysis by current in-house 
methodology, so only chip typed individuals were used for the risk scores, reducing case and control group 
sizes to 1,248/74,770 and 1,015/5,075 for the whole cohort and smoker subset, respectively. 
To account for inflation in test statistics due to cryptic relatedness and stratification within the case and 
control sample sets, we applied an LD regression based genomic control correction factor
10
 to the 
association analysis. The estimated correction factor was 1.14, 1.12 and 1.02 for the whole cohort, smoker 
subset and non-smoker subset, respectively. 
Approval for these studies was provided by the National Bioethics Committee and the Icelandic Data 
Protection Authority. 
 
Lung resection cohorts: Groningen, Laval and University of British Columbia (UBC) 
The details and subjects’ characteristics of the lung eQTL study population have been previously 
described
11,12
. All lung tissue samples were obtained in accordance with Institutional Review Board 
guidelines at the three sites: Laval University (Quebec, Canada), University of British-Columbia 
(Vancouver, Canada) and Groningen University (Groningen, The Netherlands). All patients provided written 
informed consent and the study was approved by the ethics committees of the Institut universitaire de 
cardiologie et de pneumologie de Québec and the UBC-Providence Health Care Research Institute Ethics 
Board for Laval and UBC, respectively. The study protocol was consistent with the Research Code of the 
University Medical Center Groningen and Dutch national ethical and professional guidelines (“Code of 
conduct; Dutch federation of biomedical scientific societies”; http://www.federa.org). 
 
 Briefly, Following standard microarray and genotyping quality controls, 1,111 patients were available 
including The University of British Columbia Centre for Heart and Lung Innovation (n=339, Vancouver, 
Canada), Laval University (n=409, Quebec City, Canada) and the University of Groningen (n=363, 
Groningen, The Netherlands). Gene expression profiling was performed using an Affymetrix custom array 
(GPL10379) testing 51,627 non-control probesets and normalization was performed using multi-array 
average (RMA)
13
. The expression data are available at NCBI Gene Expression Omnibus repository through 
accession numbers GSE23352, GSE23529 and GSE23545.  
Genotyping was performed on DNA extracted from blood or lung tissue using the Illumina Human1M-Duo 
BeadChip array, and imputation was performed with MaCH/Minimac software
14
 using the 1000G reference 
panel, March 2012 release. The eQTL analysis was adjusted for age, sex and smoking status in each study 
separately, and the results were meta-analysed using inverse variance weighting meta-analysis. The resulting 
eQTLs were categorized into cis-acting (less than 1Mb away from transcription start site) or trans eQTLs 
(further than 1Mb away or on a different chromosome). Genome-wide significant threshold was set using 
Benjamini-Hochberg 10% FDR.  
COPD was defined dichotomously based on an FEV1/FVC < 0.7 cutoff. Post-bronchodilator spirometry was 
used when available; otherwise, pre-bronchodilator values were used
15
. 
 
COPD case-control studies: COPDGene Study 
Details of the COPDGene Study (NCT00608764, www.copdgene.org) have been previously described
16,17
. 
Eligible subjects were of non-Hispanic white or African-American ancestry, aged 45-80 years old, with a 
minimum of 10 pack-years of smoking and no lung disease (other than COPD or asthma). Moderate to 
severe cases were defined using post-bronchodilator % predicted FEV1 < 80% predicted and FEV1/FVC < 
0.7. Genotyping was performed by Illumina (San Diego, CA) on the HumanOmniExpress array. Subjects 
were excluded for missingness, heterozygosity, chromosomal aberrations, sex check, population outliers, 
and cryptic relatedness. Genotyping at the Z and S alleles was performed in all subjects. Subjects known or 
found to have severe alpha-1 antitrypsin deficiency were excluded. Markers were excluded based on 
missingness, Hardy-Weinberg P-values, and low minor allele frequency. Imputation on the COPDGene 
cohorts was performed using MaCH and minimac (version 2012-10-09). Reference panels for the non-
Hispanic whites and African-Americans were the 1000 Genomes Phase I v3 European (EUR) and 
cosmopolitan reference panels, respectively. Variants with an r
2
 value of ≤ 0.3 were removed from further 
analysis.   
Exacerbation data were ascertained by questionnaire at enrolment; subjects were asked to recount up to 6 
exacerbation episodes which occurred during the year prior to enrolment. Cases were defined as COPD 
subjects who reported an exacerbation requiring hospitalization or an emergency room (ER) visit. Controls 
were COPD subjects who did not report any exacerbations requiring hospitalization/ER visit. 
 
COPD case-control studies: Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-
points (ECLIPSE) 
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE; SCO104960, 
NCT00292552, www.eclipse-copd.com): Details of the ECLIPSE study and genome-wide association 
analysis have been described previously 
18,19
. ECLIPSE was an observational 3-year study of COPD. Both 
cases and controls were aged 40-75 with at least a 10 pack-year smoking history without other respiratory 
diseases; cases were post-bronchodilator GOLD 2 and above COPD, and controls had normal spirometry (% 
predicted FEV1 > 85%).  Genotyping was performed using the Illumina HumanHap 550 V3 (Illumina, San 
Diego, CA). Subjects and markers with a call rate of < 95% were excluded. Population stratification 
exclusion and adjustment on self-reported white subjects was performed using EIGENSTRAT 
(EIGENSOFT Version 2.0). Imputation was performed using MaCH and minimac (version 2012-10-09) and 
the 1000 Genomes Phase I v3 European (EUR) reference panel.   
Exacerbation data were ascertained by questionnaire at enrolment; cases were defined as COPD subjects 
who reported ≥1 exacerbation requiring hospitalization during the year prior to enrolment. Control subjects 
did not report any exacerbations requiring hospitalization during the year prior to enrolment. 
 
 COPD case-control studies: National Emphysema Treatment Trial (NETT) and Normative Aging Study 
(NAS) (NETT/NAS) 
Details of the National Emphysema Treatment Trial have been described previously 
19,20
. NETT 
(www.nhlbi.nih.gov/health/prof/lung/nett/) was a multicentre clinical trial to evaluate lung volume reduction 
surgery. Enrolled subjects had severe airflow obstruction by post-bronchodilator spirometry (% predicted 
FEV1 < 45%) and evidence of emphysema on computed tomography (CT) chest imaging; exclusion criteria 
included significant sputum production or bronchiectasis. A subset of 382 self-reported white subjects 
without severe alpha-1 antitrypsin deficiency were enrolled in the NETT Genetics Ancillary Study.    
The Normative Aging Study is a longitudinal study of healthy men established in 1963 and conducted by the 
Veterans Administration (VA)
19,21
. Men aged 21 to 80 years from the greater Boston area, free of known 
chronic medical conditions, were enrolled. Smoking controls were of self-reported white ancestry and at 
least 10 pack-years of cigarette smoking with no evidence of airflow obstruction on spirometry on their most 
recent visit. Genotyping for NETT-NAS was performed using the Illumina Quad 610 array (Illumina, San 
Diego, CA), with quality control, population stratification adjustment, as described previously. Imputation 
was performed using MaCH and minimac (version 2012-10-09) and the 1000 Genomes Phase I v3 European 
(EUR) reference panel.  
Exacerbations were ascertained using Medicare billing data during the year prior to enrolment. Subjects who 
were hospitalized for COPD exacerbations were considered cases; subjects who were not hospitalized for 
COPD exacerbations during the year before enrolment were considered controls. 
 
COPD case-control studies: NORWAY-GenKOLS 
Details on the Norwegian GenKOLS (Genetics of Chronic Obstructive Lung Disease, GSK code RES11080) 
study have been described previously
22
. Subjects with > 2.5 pack years of smoking history were recruited 
from Bergen, Norway; cases had post-bronchodilator GOLD 2 or greater disease, while controls had normal 
spirometry; subjects with severe alpha-1 antitrypsin deficiency and other lung diseases (aside from asthma) 
were excluded.  Genotyping was performed using Illumina HumanHap 550 arrays (Illumina, San Diego, 
CA), with quality control, population stratification adjustment as previously described. Imputation was 
performed using MaCH and minimac (version 2012-10-09) and the 1000 Genomes Phase I v3 European 
(EUR) reference panel. 
Exacerbation data were ascertained by questionnaire at enrolment. Subjects who reported ≥1 hospitalization 
related to respiratory symptoms in the year prior to enrolment were considered cases. Subjects who did not 
report any hospitalizations for respiratory symptoms were considered controls. 
eMR studies: Geisinger-Regeneron DiscovEHR Study (DiscovEHR) 
The DiscovEHR
23
 collaboration between the Regeneron Genetics Center and Geisinger Health System 
MyCode Community Health Initiative couples high throughput genetic data to a Healthcare Provider 
Organization utilizing longitudinal electronic health records (EHR). The study was approved by the 
institutional review board at the Geisinger Health System. A subset of individuals with available genome-
wide genotyping data was included in the current study. Genotyping was performed using the Illumina 
OmniExpressExome BeadChip, with standard QC metrics applied. Imputation was performed with 
IMPUTE2 v2.3.2 using the 1000 Genomes cosmopolitan dataset (June 2014 version). COPD cases were 
defined using a combination of ICD-9 diagnosis codes and available lung function testing. ICD-9–based 
diagnoses required one or more of the following: a problem-list entry of the diagnosis code or an encounter 
diagnosis code entered for two separate outpatient visits on separate calendar days. To be considered a 
COPD case, individuals were required to have spirometry-confirmed airflow obstruction (FEV1/FVC< 
0.70) and any of the following ICD-9 diagnoses codes: 490, 491.0, 491.1, 491.8, 491.9, 492.8, 492.0, 
491.22, 493.21, 491.21, 493.22, 491.20, 493.20 and 496. Controls were defined as individuals without an 
ICD-9 diagnosis code of either asthma or COPD. Asthmatics were excluded from the control group given 
that the shared features of these diseases complicate their diagnosis in a clinical setting. Both cases and 
controls were restricted to individuals of European genetic ancestry and with age > 40. For exacerbation 
analyses, cases were COPD patients (as described above) with one or more inpatient admissions attributed to 
COPD; controls were COPD patients with no inpatient admissions attributed to COPD. 
 
 eMR studies: Mount Sinai BioMe Biobank (BioMe) 
The BioMe Biobank is an ongoing, prospective, hospital- and outpatient- based population research program 
operated by The Charles Bronfman Institute for Personalized Medicine (IPM) at The Icahn School of 
Medicine at Mount Sinai and has enrolled over 33,000 participants since September 2007. BioMe is an 
Electronic Medical Record (EMR)-linked biobank that integrates research data and clinical care information 
for consented patients at The Mount Sinai Medical Center, which serves diverse local communities of upper 
Manhattan with broad health disparities. BioMe populations include 25% of African American ancestry 
(AA), 36% of Hispanic Latino ancestry (HL), 30% of white European ancestry (EA), and 9% of other 
ancestry. The BioMe disease burden is reflective of health disparities in the local communities. BioMe 
operations are fully integrated in clinical care processes, including direct recruitment from clinical sites 
waiting areas and phlebotomy stations by dedicated recruiters independent of clinical care providers, prior to 
or following a clinician standard of care visit. Recruitment currently occurs at a broad spectrum of over 30 
clinical care sites.  
Information on COPD cases status (ICD9 codes), height, age and sex was derived from participants’ EMR. 
Case/control selection was restricted to individuals with age > 40 years, available genotyping data, as well as 
sex, height and smoking data. Case/control definition was carried out based on information retrieved from 
EMRs: COPD cases were defined as individuals with records of ICD-9 codes for COPD (491.xx-492.xx, 
496.xx), whereas COPD controls were defined as individuals with none of the above listed ICD-9 codes for 
COPD. 
Exacerbation cases and controls were defined as individuals with and without a primary COPD diagnosis 
(based on the ICD codes) at an inpatient visit, respectively. 
BioMe participants were genotyped with the Illumina HumanOmniExpressExome-8 v1.0 BeadChip array 
and imputed to the 1000 Genomes Project Phase 1 (March 2012) reference panel using IMPUTE2. SNPs of 
interest were extracted using gtool [http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html]. Out of 
the 95 COPD variants, 93 were available in the BioMe data set either directly genotyped or imputed with 
good imputation quality (info>0.7), for two variants, proxies were used (rs12438269 for rs66650179  
[r
2
=0.618] and rs62070270 for rs59835752  [r
2
=0.999]). Association analyses were carried out using 
generalized linear models in R stratified by self-reported ancestry (EA: 207 COPD cases and 1,817 
controls). 
 
Chinese ancestry: China Kadoorie Biobank prospective cohort (CKB) 
The CKB study involved 512,891 participants, aged 30-79 years, recruited between 2004-8 from 10 diverse 
regions of China and who gave their informed written consent to proceed to an extensive collection of 
clinical and environmental data at baseline
24
. Subsets of ~25,000 survivors were actively followed up in 
2008 (1
st
 resurvey) and in 2013-14 (2
nd
 resurvey) with additional collection of clinical and blood samples. 
Furthermore, all participants were followed up for cause-specific mortality and episodes of hospitalisation 
using:
24
 (i) cross-checking with official death certificates collected by the regional Center for Disease 
Control (CDC) to code causes of death according to World Health Organisation ICD-10 codes; (ii) linkage 
with established disease registries to supplement information on non-fatal events for 4 major diseases 
(stroke, ischaemic heart disease (IHD), diabetes, and cancer); and (iii) electronic records from the the 
national Chinese health insurance (HI) system, to retrieve additional disease and hospitalisation events (e.g. 
COPD).  
A genotyping study (hereafter¸ called SNP-Panel) of 384 single-nucleotide polymorphisms (SNPs) was 
conducted in 93,208 (after quality control [QC]) subjects in 2013-14. SNPs were selected based on previous 
association (mainly GWAS) with chronic diseases (e.g. stroke, IHD) and intermediate phenotypes (e.g. lung 
function, blood pressure, BMI), metabolic pathways (e.g. Vitamin D) and risk exposure (e.g. smoking). In 
addition, using a customised Affymetrix Axiom
®
 CKB array (optimised for use with Han Chinese subjects) 
including 700,000 markers before imputation (including all markers included on the SNP-panel), a 
genotyping study (GWAS) was conducted in 2014-15 in 32,201 (after QC) individuals, including 14,000 
with SNP-panel data. Subjects were selected for the GWAS who were part of a stroke nested case/control 
study (20,000), had additional phenotypes of interest (ischaemic heart disease, 2,000; COPD 
exacerbations, ~5,000), and ~5,000 participants who attended the 2
nd
 resurvey. Participants with prior self-
reported cardiovascular disease, cancer and/or statin use at baseline were excluded. 
  
We excluded participants who were <40 years of age and those with prior cardiovascular diseases, cancer 
and/or statin use to be consistent with the exclusion criteria for the GWAS data (see above). Only pre-
bronchodilator spirometry measurements were available for the analysis. GOLD 2-4 was defined based on 
(i) a FEV1/FVC ratio<70; and (ii) % predicted FEV1 values as derived from Quanjer et al.
25
 For individuals 
with lung function measurements available at the baseline and in the 1
st
 and/or 2
nd
 follow-ups, we used the 
highest lung function measurement for the analysis. Exacerbation status was defined as any hospitalisation 
for COPD exacerbation, as recorded through the Chinese health insurance system.  
The GWAS dataset (n=32,201) was combined with a non-overlapping dataset from the SNP-Panel study 
(n=78,884), which yielded a combined dataset of 111,085 individuals with genetic data. Based on the list of 
SNPs provided by UK BiLEVE, we were able to identify 71 lead or proxy SNPs in the CKB dataset.  
We identified those COPD cases and controls for whom genetic data were available, which yielded a dataset 
of 87,966 individuals for the COPD analysis. The same approach was used to select exacerbation cases and 
controls (n=10,566).  
 
In single variant analysis, logistic regression of each SNP on (i) COPD and (ii) COPD exacerbation status 
was performed adjusting for sex, age, height, geographical region (n=10) and disease status (to account for 
ascertainment of a subset of the cohort based on disease status; 5 categories: ischaemic stroke, intra-cerebral 
haemorrhage, subarachnoid haemorrhage; ischaemic heart disease; no cardiovascular disease ascertainment). 
Inflation estimates () corresponding to COPD and COPD exacerbation status analyses were derived from 
the results of array-wide association using the GWAS dataset and were estimated according to the LDscore 
intercept method, with =1.0302 for COPD and =1.0056 for COPD exacerbation. Adjusted inflation 
estimates for SNPs also present on the SNP-Panel were derived based on the appropriate numbers of cases 
and controls. Standard errors of the logOR for these analyses were adjusted for the estimated inflation.  
In the genetic risk score analysis, we restricted the analysis to the GWAS subsample with genotypes for all 
SNPspresent in the single variant analysis, except for one (rs153916) that was only available in the SNP-
Panel dataset; the GRS analysis thus included 70 SNPs. Missing genotypes were imputed as the mean 
genotype (2 x MAF) for the region for that individual, based on MAFs derived from a pruned GWAS 
dataset with relatives (3
rd
 cousin or closer) excluded. Logistic regression of the risk score on COPD and 
COPD exacerbation status adjusting for sex, age, age
2
, height, regions (n=10) and disease status (n=5; see 
above) was conducted. Standard errors for the logOR were again adjusted for the estimated inflation. 
Data management was conducted using Stata v.13.1 (Stata Corp, TX, USA) and Plink 1.90. Single variant 
and genetic risk score analyses were conducted using Plink 1.90 and Stata v.13.1, respectively. 
 
Lung Health Study (LHS) 
The LHS was a multicenter clinical study to evaluate the effect of bronchodilators and smoking cessation on 
lung function decline in current smokers with mild-moderate COPD
26,27
.  
The details of genotyping and quality control have been previously described
28
. Briefly, samples were 
genotyped using the Illumina Human660WQuad v.1_A BeadChip. Overall, 98.4 % of samples (n = 4,181) 
passed initial quality control standards and genotypes were released for 559,766 SNPs. Imputation was 
undertaken with the software IMPUTE2
5
 using the all ancestries 1000G reference panel, March 2012 
release
29
.  
 
Hospitalizations were defined in the following way. For all hospitalizations, copies of essential documents 
were obtained from hospital record rooms. Records that made significant mention of respiratory or 
cardiovascular disease (CVD) or cancer were forwarded to the study's mortality and morbidity review board 
for definitive coding. Thus, "respiratory" hospitalizations were all deemed by this board as being primarily 
driven by a respiratory condition (e.g. COPD exacerbation and pneumonia)
30
. Testing for association with 
exacerbations defined as respiratory hospitalizations was performed using data on the total number of 
respiratory hospitalizations reported on LHS study participants at year 5.  
 
 Studies contributing analyses of lung function in children 
Avon Longitudinal Study of Parents and Children (ALSPAC) 
The Avon Longitudinal Study of Parents and Children (ALSPAC) recruited 14,541 pregnant women resident 
in Avon, UK with expected dates of delivery 1st April 1991 to 31st December 1992. 14,541 is the initial 
number of pregnancies for which the mother enrolled in the ALSPAC study and had either returned at least 
one questionnaire or attended a “Children in Focus” clinic by 19/07/99. Of these initial pregnancies, there 
was a total of 14,676 foetuses, resulting in 14,062 live births and 13,988 children who were alive at 1 year of 
age.  
When the oldest children were approximately 7 years of age, an attempt was made to bolster the initial 
sample with eligible cases who had failed to join the study originally. As a result, when considering 
variables collected from the age of seven onwards (and potentially abstracted from obstetric notes) there are 
data available for more than the 14,541 pregnancies mentioned above.  
The number of new pregnancies not in the initial sample (known as Phase I enrolment) that are currently 
represented on the built files and reflecting enrolment status at the age of 18 is 706 (452 and 254 recruited 
during Phases II and III respectively), resulting in an additional 713 children being enrolled. The phases of 
enrolment are described in more detail in the cohort profile paper31. 
The total sample size for analyses using any data collected after the age of seven is therefore 15,247 
pregnancies, resulting in 15,458 foetuses. Of this total sample of 15,458 fetuses, 14,775 were live births and 
14,701 were alive at 1 year of age. 
Spirometry was performed using the Vitalograph Spirotrac IV system (Vitalograph, Maids Moreton UK) and 
the hand-held Medikro Spirostar USB spirometer (Medikro, Kuopio, Finland) using methods described 
previously32,33. The machines were calibrated every day the medical examination took place. FVC and FEV1 
were measured in sitting position, while wearing a nose clip, by trained personnel, according to the 
ATS/ERS guidelines. For each child, at least three acceptable manoeuvres had to be obtained. The best 
results of three acceptable & repeatable (FVC +/- 150mL) flow-volume curves were accepted after post hoc 
quality control by a respiratory physician. 
Genotyping details are described in Kemp et al. (2014)34. Briefly, a total of 9,912 subjects were genotyped 
using the Illumina HumanHap550 quad genome-wide SNP genotyping platform by the Wellcome Trust 
Sanger Institute, Cambridge, UK and the Laboratory Corporation of America (LabCorp Holdings., 
Burlington, NC, USA). PLINK software (v1.07) was used to carry out quality control measures35. 
Individuals were excluded from further analysis on the basis of having incorrect gender assignments, 
minimal or excessive heterozygosity (,0.320 and .0.345 for the Sanger data and ,0.310 and .0.330 for the 
LabCorp data), disproportionate levels of individual missingness (.3%), evidence of cryptic relatedness 
(.10% IBD) and being of non-European ancestry (as detected by a multidimensional scaling analysis seeded 
with HapMap 2 individuals). EIGENSTRAT analysis revealed no additional obvious population 
stratification and genome-wide analyses with other phenotypes indicate a low lambda)36. SNPs with a minor 
allele frequency of ,1% and call rate of ,95% were removed. Furthermore, only SNPs that passed an exact 
test of Hardy–Weinberg equilibrium (P. > 5x10^-7) were considered for analysis. After quality control, 8,365 
unrelated individuals who were genotyped at 500,527 SNPs were available for analysis. Known autosomal 
variants were imputed with Markov Chain Haplotyping software (MACH 1.0.16)37,38, using CEPH 
individuals from phase II of the HapMap project (hg18) as a reference set (release 22)39. 
Please note that the ALSPAC study website contains details of all the data that is available through a fully 
searchable data dictionary (http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/). 
Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local 
Research Ethics Committees. 
  Males:Females Age (mean 
(SD) [range]) 
FEV1 (l) 
(mean (SD) 
[range]) 
FVC (l) (mean 
(SD) [range]) 
FEV1/FVC 
(mean (SD) 
[range]) 
ALSPAC 2547:2515 8.64 (0.30)  
[7.42-10.33] 
1.70 (0.26) 
[0.68-2.80] 
1.93 (0.32) 
[0.77-3.13] 
0.88 (0.06) 
[0.50-1] 
 
Raine study 
The Raine Study is a cohort of children formed in 1989-91 where approximately 2900 pregnant women 
volunteered to be part of the study at King Edward Memorial Hospital in Perth, Australia. Ethical approval 
was obtained from the University of Western Australia Human Research Ethics Committee. 
Raine samples were genotyped using Illumina 660W Quad Array. Individuals genotyped were excluded if 
they had low genotyping success (>3% missing), excessive heterozygosity (which may indicate sample 
contamination), or had gender discrepancies between the core data and genotyped data. Individuals who 
were related with π > 0.1875 (in between second and third degree relatives – e.g. between half siblings and 
cousins) were investigated and the individual with a lower proportion of missing data was kept in the data 
set. Plate controls and replicates were removed from the data set. With replicates, the sample with a lower 
proportion of missing data was kept in the data set. A total number of 1494 individuals passed QC criteria 
and were used in genetics analyses. GWAS SNP QC was carried out in accordance to the Wellcome Trust 
Case Control Consortium thresholds (HWE p < 5.7E-07, call rate < 95%, MAF < 1%, A/T and G/C SNPs 
were also removed due to possible strand ambiguity). Imputation was then performed against the 1000G 
Phase 1 v3 reference using MACH/Minimac. 
 
 Males:Females Age (mean 
(SD) [range]) 
FEV1 (l) 
(mean (SD) 
[range]) 
FVC (l) (mean 
(SD) [range]) 
FEV1/FVC 
(mean (SD) 
[range]) 
Raine 590:630 8.1 (0.35) 
[7.13-9.98] 
1.56 (0.25) 
[0.59-2.39] 
1.65 (0.28) 
[0.59-2.92] 
0.95 (0.05) 
[0.65-1.07] 
 
 
 
  
 Supplementary Figures 
Supplementary Figure 1: Quantile-Quantile (QQ)-plots and genomic inflation factor (λ) for discovery 
stage 1 (n= 48,943) association tests of FEV1, FVC and FEV1/FVC meta-analyses of heavy and never 
smokers. 
    
 
  
 Supplementary Figure 2: Comparison of effect sizes for lung function associated variants in adults and children.  a) Results available in children for 81 
of the 97 variants with imputation quality >0.5 (79 variants in ALSPAC and 35 in Raine). Correlation coefficient r =0.417.  Filled shapes indicate P<0.05 in 
children A genetic risk score of all 81 variants showed a per risk allele β (s.e.) on FEV1, FVC and FEV1/FVC of -0.0162 (0.003955) (P=4.14x10
-5
), -0.0005 
(0.003965) (P=0.894) and -0.0229 (0.003541) (P=1.04x10
-10
). The two clear outliers were rs72724130 (novel signal in an intron of MGA, imputation 
quality=0.65, MAF=4.9% in ALSPAC) and rs113473882 (previously reported signal in an intron of LTBP4, imputation quality =0.76, MAF 1.34% in 
ALSPAC). Neither were available in Raine. Exclusion of these two SNPs gives a correlation coefficient r=0.71 for the remaining 79 variants.  b) Seventy-three 
of the 81 variants had imputation quality >0.8 (71 variants in ALSPAC and 35 in Raine). Correlation coefficient r =0.651.  Filled shapes indicate P<0.05 in 
children.  A genetic risk score of all 73 variants showed a per risk allele β (s.e.) on FEV1, FVC and FEV1/FVC of -0.0177 (0.0040) (P=1.03x10
-5
), -0.0037 
(0.0041) (P=0.366) and -0.0213 (0.0037) (P=1.27x10
-8
).  
 a 
 
 
 
 
 
 
b 
 Supplementary Figure 3: Summary of Bayesian fine-mapping to 95% credible sets for lung function 
signals. The 95% credible set is the set of variants that are 95% likely to contain the underlying causal 
variant based on Bayesian refinement.  Following exclusion of signals in the HLA region, one chromosome 
X signal and 23 previously-reported signals which did not reach P<10
-5
 for association with lung function in 
stage 1 of this study, 67 signals underwent Bayesian fine-mapping to identify the 95% credible set. A: 
Numbers of signals fine-mapped to 1, 2-5, 6-10, etc variants. B: Numbers of signals for which a single 
variant accounts for >=95%, 50-95%, 20-50%, etc, of the posterior probability. 
  
 Supplementary Figure 4: Region plots with credible sets shown for 43 novel variants. Variants in the 
95% credible set are shown as filled circles, those not in the credible set as open circles with the span of the 
credible set shaded in green on the gene track below. Credible sets were not calculated for 2 signals in the 
HLA region on chromosome 6 (labelled as LST1 and HLA-DQB1). Where a “conditioned on” variant is 
given, the novel signal is a secondary or tertiary signal after conditioning and accordingly the region plot 
shows –log10 P values from stage 1 after conditioning on the corresponding variant. 
 
  
  
  
  
  
  
  
  
 Supplementary Figure 5: Region plots with credible sets shown for 26 previously-reported signals that 
reached P <10
-5
 in stage 1 in this study and are not in the HLA region. Variants in the 95% credible set 
are shown as filled circles, those not in the credible set as open circles with the span of the credible set 
shaded in green on the gene track below. Where a “conditioned on” variant is given, the previously 
discovered signal is conditioned on a novel secondary signal. 
 
  
  
  
  
  
 Supplementary Figure 6: Region plots for imputation of HLA haplotypes and amino acids. Results are 
shown for FEV1 (a and b) and FEV1/FVC (c and d) both before and after conditioning on HLA-DQβ1 amino 
acid position 57. 
a) FEV1 (no conditioning) 
 
b) FEV1 conditioned on HLA-DQβ1 amino acid position 57 
 
 c) FEV1/FVC (no conditioning) 
 
d) FEV1/FVC conditioned on HLA-DQβ1 amino acid position 57 
 
 
 
 Supplementary Figure 7: Log odds ratio of COPD risk in UK Biobank samples excluding individuals 
with a doctor diagnosis of asthma (n=56,195) vs. log odds ratio of COPD risk in all available UK 
Biobank samples (n=64,484) for 97 lung function signals. Error bars are the standard errors of the effect 
estimates. 
 
  
  
Supplementary Figure 8: Distribution of a) FEV1, b) FVC and c) FEV1/FVC in stage 1 (UK BiLEVE) 
for 48,493 stage 1 samples. Plots show distributions before adjustment (Raw), residuals after adjusting for 
covariates (age, age
2
, sex, height and first 10 ancestry principal components) and residuals after rank 
inverse-normal transformation. Data are presented separately for heavy (top row) and never smokers 
(bottom row). 
a) FEV1 
 
 b) FVC 
 
c) FEV1/FVC 
 
  
 
 
 
 
 Supplementary Figure 9: Power calculations. Statistical power (y-axis) for detecting genome-wide significant association under an additive genetic model in 
a population of size 48,493 for varying minor allele frequency (MAF, coloured lines) and effect sizes (x-axis). Simplifying assumptions have been utilised to 
produce conservative estimates. A single stage design in a population drawn from a general population at random and a P-value threshold 5x10
-8
 is assumed. 
Power would be expected to be greater with enrichment for extremes values of a quantitative outcome variable, and with a higher p-value threshold and follow-
up in an independent population. A study with such conservative assumptions applied would be powered to detect variants of and MAF≥5% and modest effect 
size (e.g. power >90% at MAF 5% and effect size 0.1 SD) and powered to detect lower frequency variants that have a larger effect size (e.g. power >75% for 
MAF 1% and effect size 0.2 SD). 
 
 
 
 
 Supplementary Figure 10:  Comparison of effect estimates between SpiroMeta-CHARGE stage 2
40
 
and UK BiLEVE stage 1 for 26 variants reported for lung function before UK BiLEVE. Error bars are 
the standard errors of the effect estimates. Betas are quantiles of normal distribution (phenotypes rank 
inverse-normal transformed). 
 
 
 Supplementary Tables  
Supplementary Table 1: Summaries of stage 1 (UK BiLVE) and stage 2 (UK Biobank, SpiroMeta and UKHLS) studies. *Details of all 17 studies that 
contributed to SpiroMeta can be found in Soler Artigas et al 2015
41
 
Study Name Smoking group 
Lung function 
group n n (%) Male 
Smokers, 
n (%) Age, mean (SD) 
FEV1, litres. mean 
(SD) 
FVC, litres. mean 
(SD) 
FEV1/FVC, mean 
(SD) 
Stage 1 
UK BiLEVE 
All 48,943 24,489 (50.0%) 24,460 (50.0%) 56.9 (7.89) 2.65 (0.87) 3.59 (1.05) 0.733 (0.081) 
Heavy  smokers 
High  4,907 2,459 (50.1%) 4,907 (100%) 56.9 (7.90) 3.49 (0.72) 4.49 (0.96) 0.778 (0.044) 
Average 9,803 4,908 (50.1%) 9,803 (100%) 56.9 (7.89) 2.68 (0.56) 3.62 (0.78) 0.743 (0.054) 
Low 9,750 4,886 (50.1%) 9,750 (100%) 56.9 (7.88) 1.93 (0.55) 2.92 (0.75) 0.663 (0.096) 
Never smokers 
High 4,902 2,457 (50.1%) 0 56.9 (7.90) 3.83 (0.73) 4.85 (0.95) 0.791 (0.041) 
Average 9,831 4,905 (49.9%) 0 56.9 (7.89) 2.92 (0.57) 3.81 (0.79) 0.769 (0.047) 
Low 9,750 4,874 (50.0%) 0 56.9 (7.88) 2.05 (0.54) 2.92 (0.79) 0.707 (0.084) 
Stage 2 
UK Biobank 49,727 20,682 (41.6%) 31,952 (64.3%) 56.4 (7.95) 2.85 (0.71) 3.75 (0.91) 0.762 (0.055) 
SpiroMeta* 38,199 * * * * * * 
UKHLS 7,449 3,293 (44.2%) 4,509 (60.5%) 53.10 (15.94) 2.89 (0.90) 3.83 (1.08) 0.753 (0.090) 
 
  
 Supplementary Table 2: LD score regression analysis to estimate extent of overlap between SpiroMeta 
(stage 2) and the two UK Biobank subsets; UK BiLEVE (stage 1) and UK Biobank (stage 2).  Results 
for the regression of each trait FEV1, FVC and FEV1/FVC against the LD score of each variant are shown. 
Total Observed scale h2: Estimate of heritability, Lambda GC: Usual lambda used for genomic control: 
inflation due to both confounding and polygenicity, Mean χ2: Mean χ2 statistic from the association testing, 
Intercept: Intercept of the LD score regression (estimate of inflation due to confounding but not 
polygenicity; suggested as a more appropriate genomic-control factor), Ratio: Proportion of total inflation 
due to confounding (Intercept-1)/(Mean χ2-1). 95% confidence intervals are shown in brackets. A) Meta-
analysis of UK BiLEVE (stage 1) and UK Biobank (stage 2) shown for comparison as overlapping samples 
were excluded. B) Meta-analysis of UK BiLEVE and SpiroMeta, C) Meta-analysis of UK Biobank and 
SpiroMeta, D) Genetic covariance intercept (95% C.I.) for bivariate LD score regression 
 
A) Meta-analysis of UK BiLEVE (stage 1) and UK Biobank (stage 2): 
N = 98,670 FEV1 FVC FEV1/FVC 
Total Observed scale h2 0.212 (0.187, 0.236) 0.209 (0.186, 0.233) 0.230 (0.198, 0.263) 
Lambda GC 1.344 1.372 1.331 
Mean χ2 1.498 1.496 1.548 
Intercept 1.040 (1.018, 1.062) 1.049 (1.025, 1.072) 1.055 (1.030, 1.079) 
Ratio 0.080 (0.036, 0.124) 0.098 (0.050, 0.146) 0.100 .055, 0.144) 
B) Meta-analysis of UK BiLEVE and SpiroMeta 
N = 87,142 FEV1 FVC FEV1/FVC 
Total Observed scale h2 0.208 (0.184, 0.233) 0.210 (0.186, 0.234) 0.185 (0.157, 0.213) 
Lambda GC 1.297 1.313 1.24 
Mean χ2 1.427 1.419 1.371 
Intercept 1.036 (1.016, 1.055) 1.026 (1.006, 1.046) 1.025 (1.002, 1.048) 
Ratio 0.084 (0.039, 0.128) 0.062 (0.015, 0.110) 0.67 .006, 0.129) 
C) Meta-analysis of UK Biobank and SpiroMeta 
N = 87,926 FEV1 FVC FEV1/FVC 
Total Observed scale h2 0.158 (0.136, 0.179) 0.157 (0.136, 0.178) 0.169 (0.142, 0.196) 
Lambda GC 1.25 1.25 1.236 
Mean χ2 1.325 1.326 1.356 
Intercept 1.029 (1.008, 1.050) 1.031 (1.010, 1.052) 1.038 (1.018, 1.059) 
Ratio 0.088 (0.024, 0.152) 0.096 (0.032, 0.160) 0.108 .050, 0.166) 
 
D) Genetic covariance intercept (95% C.I.) for bivariate LD score regression 
 
FEV1 FVC FEV1/FVC 
UK BiLEVE & UK Biobank 0.008 (-0.008, 0.023) 0.021 (0.005, 0.036) 0.007 (-0.011, 0.026) 
UK BiLEVE & SpiroMeta 0.012 (-0.002, 0.026) 0.006 (-0.008, 0.021) 0.001 (-0.014, 0.015) 
UK Biobank & SpiroMeta 0.009 (-0.005, 0.024) 0.013 (-0.000, 0.026) 0.007 (-0.007, 0.022) 
 Supplementary Table 3: Full results for all 81 variants followed up in stage 2. The 81 variants showing suggestive association (P < 5x10
-7
) with a lung 
function quantitative trait in discovery, their lung function association results in stage 1 and stage 2 studies separately, the results of the meta-analysis of the 
stage 2 studies and the meta-analysis of the stage 1 and stage 2 studies are shown. The 43 variants with P < 5x10
-8
 following meta-analysis of Stage 1 and Stage 
2 are presented first (sorted by chromosome and position), followed by the remaining 38 signals with P > 5x10
-8
 following meta-analysis of Stage 1 and Stage 
2. Values are missing from stage 2 studies where there was quality control failure due to poor imputation (info < 0.5) or low minor allele count (MAC < 3). 
Where the discovery variant was not available in replication cohorts but a proxy with r
2
 > 0.7 was available, the proxy was used for replication in all cohorts 
(proxies are marked with * in the list of discovery variants). For discovery the standard errors and P values are genomic control (GC) corrected except for 
conditional analyses (“Conditioned on” column non-empty) where unadjusted standard errors and P values are given. GC corrected results were used for 
SpiroMeta 1000 genomes. Unadjusted results are used for UK Biobank and UKHLS where genome-wide inflation factors were not available. In the meta-
analysis of the Stage 2 replication cohorts the 39 variants showing independent replication (Bonferroni correction for 81 tests: P < 6.17x10
-4
) have P value in 
bold. In the meta-analysis of the discovery and replication stages (Stage 1 + 2) the variants showing genome-wide significant association (P < 5x10
-8
) have P 
value in bold. 
See accompanying Excel file. 
  
 Supplementary Table 4: Stage 1 results for 97 variants associated with lung function (all traits). The 97 variants showing association with lung function 
comprising (a) 43 novel variants and (b) 54 previously-reported variants (the most significant variant in this study for the previously reported signal is given). 
Association results are from the discovery stage (48,943 UK BiLEVE samples). In (a), the trait for which the variant showed the most significant association is 
given in the “trait” column and the effect and P value for the reported trait is in bold. In (b), the trait for which the variant was previously reported as showing 
the most significant association is given in the “trait” column and the effect and P value for the reported trait is in bold. The effect estimate beta is on the 
inverse-normal rank scale, standard errors and P values are Genomic Control (GC) corrected for unconditional association results. In (a), the variant upon 
which the association was conditioned is given in the “Conditioned on” column (conditional results are not GC corrected). The nearest genes, or location of 
variant within the gene, is indicated. In (b), the published study that first reported the signal is given. *The listed gene is the gene name used to describe that 
signal in the previous study publication. References for previous studies are as follows: Wilk et al (2009)
42
, Repapi et al (2010)
43
, Hancock et al (2010)
44
, Soler 
Artigas et al (2011)
40
, Loth et al (2014)
45
, Wain et al (2015)
46
, Soler Artigas et al (2015)
41
.  
See accompanying Excel file. 
 
  
 Supplementary Table 5: Bayesian estimation of 95% credible sets. A summary of the number of variants 
in the 95% credible sets for the novel association signals and the previous signals having association P < 10
-
5
. The table includes the number of variants in the credible set, the top ranked variant and its posterior 
probability. The posterior probabilities and the credible sets were calculated as described in Wakefield
47
. Six 
HLA signals, 1 chromosome X signal and 23 previously-reported signals with P > 10
-5
 could not be refined 
using this method resulting in sets being defined for 41 novel signals and 26 previously-reported signals. 
Conditional results were used for rs1192404 (conditioned on rs12140637), rs13110699 (rs2045517), 
rs2045517 (rs13110699), rs10515750 (rs1990950), rs1990950 (rs10515750), rs7753012 (rs148274477) and 
rs148274477 (rs7753012). The posterior probabilities of rs2045517 (rank: 20), rs10516526 (114), rs7753012 
(2) and rs7218675 (20) are 0.01316, 0.00404, 0.1959 and 0.0214 respectively. 
Sentinel variant 
ID and Genomic 
position 
Locus Number of 
variants in 
credible set 
Trait Nearest genes to 
Sentinel variant 
Top ranked 
variant 
(Posterior 
probability) 
Novel signals 
rs17513135 
chr1: 40035686 
Chr 1: 39527963-40113043 
104 
FEV1/FVC LOC101929516 (intron) Sentinel 
(0.09118) 
rs1192404 
chr1: 92068967 
Chr 1: 92016515-92112240 
12 
FEV1/FVC CDC7/TGFBR3 Sentinel 
(0.149) 
rs12140637 
chr1: 92374517 
Chr 1:92330156-92472668 
12 
FEV1/FVC TGFBR3/BRDT Sentinel 
(0.1021) 
rs200154334 
chr1: 118862070 
Chr 1:118824762-118942956 
21 
FVC SPAG17/TBX15 Sentinel 
(0.2355) 
rs6688537 
chr1: 239850588 
Chr 1:239773921-239939160 
60 
FEV1/FVC CHRM3 (intron) Sentinel 
(0.0523) 
rs61332075  
chr2: 239316560 Chr 2:239198478-239500420 115 FEV1/FVC TRAF3IP1/ASB1 
Sentinel 
(0.2538) 
rs1458979  
chr3: 55150677 Chr 3:55124454-55183751 7 FEV1/FVC CACNA2D3/WNT5A 
Sentinel 
(0.2813) 
rs1490265  
chr3: 67452043 Chr 3:67406108-67481222 16 FVC SUCLG2 (intron) 
Sentinel 
(0.1378) 
rs2811415  
chr3: 127991527 Chr 3:127688264-128092441 197 FEV1/FVC EEFSEC (intron) 
Sentinel 
(0.01469) 
esv2660202  
chr3: 168738454 Chr 3:168635231-168885010 119 FEV1/FVC 
LOC100507661/MECO
M 
Sentinel 
(0.03174) 
rs13110699  
chr4: 89815695 Chr 4:89775892-89959645 43 FEV1/FVC FAM13A (intron) 
Sentinel 
(0.0874) 
rs91731  
chr5: 33334312 Chr 5:33182002-33424894 52 FVC LOC340113/TARS 
Sentinel 
(0.04772) 
rs1551943  
chr5: 52195033 Chr 5:52152346-52257838 9 FEV1/FVC ITGA1 (intron) 
Sentinel 
(0.3193) 
rs2441026  
chr5: 53444498 Chr 5:53419498-53518744 20 FVC ARL15 (intron) 
Sentinel 
(0.4559) 
rs7713065  
chr5: 131788334 Chr 5:131723241-131834757 36 FEV1/FVC C5orf56 (intron) 
Sentinel 
(0.07636) 
rs3839234  
chr5: 148596693 Chr 5:148568202-148677363 33 FEV1 ABLIM3 (intron) 
Sentinel 
(0.1756) 
rs10515750  
chr5: 156810072 Chr 5:156611712-156970148 47 FEV1/FVC CYFIP2 (intron) 
Sentinel 
(0.05234) 
rs28986170 
chr6: 31556155 Chr 6:31296753-32229882 HLA FEV1/FVC LST1 (intron) 
HLA 
rs114229351 
chr6: 32648418 Chr 6:32512879-32693100 HLA FEV1 HLA-DQB1/HLA-DQA2 
HLA 
rs141651520  
chr6: 73670095 Chr 6:73630333-73744982 7 FEV1/FVC KCNQ5 (intron) 
Sentinel 
(0.1527) 
rs10246303  
chr7: 7286445 Chr 7:7196968-7311445 18 FEV1/FVC C1GALT1 (3’ UTR) 
Sentinel 
(0.136) 
 Sentinel variant 
ID and Genomic 
position 
Locus Number of 
variants in 
credible set 
Trait Nearest genes to 
Sentinel variant 
Top ranked 
variant 
(Posterior 
probability) 
rs72615157  
chr7: 99635967 Chr 7:99608739-99874854 36 FEV1/FVC ZKSCAN1 (3’ UTR) 
Sentinel 
(0.306) 
rs12698403  
chr7: 156127246 Chr 7:156080037-156159055 7 FEV1 LOC389602/LOC285889 
Sentinel 
(0.2177) 
rs7872188  
chr9: 4124377 Chr 9:4094707-4173531 24 FEV1 GLIS3 (intron) 
Sentinel 
(0.1887) 
rs10870202  
chr9: 139257411 Chr 9:139213707-139343071 9 FVC DNLZ (intron) 
Sentinel 
(0.4887) 
rs3847402  
chr10: 30267810 Chr 10:30222165-30306732 58 FEV1/FVC SVIL/KIAA1462 
Sentinel 
(0.03702) 
rs7095607  
chr10: 69957350 Chr 10:69887278-69990177 61 FVC MYPN (intron) 
Sentinel 
(0.03546) 
rs2509961  
chr11: 62310909 Chr 11:62284787-62443921 78 FEV1 AHNAK (intron) 
Sentinel 
(0.04564) 
rs11234757  
chr11: 86443072 Chr 11:86403024-86557868 14 FEV1 ME3/PRSS23 
Sentinel 
(0.1066) 
rs567508  
chr11: 126008910 Chr 11:125983910-126053787 9 FEV1 CDON/RPUSD4 
Sentinel 
(0.3015) 
rs1494502  
chr12: 65824670 Chr 12:65730543-65867258 39 FEV1 MSRB3 (intron) 
Sentinel 
(0.05955) 
rs113745635  
chr12: 95554771 Chr 12:95336610-95733206 18 FEV1/FVC FGD6 (intron) 
Sentinel 
(0.07072) 
rs35506  
chr12: 115500691 Chr 12:115457443-115529071 4 FVC TBX3/MED13L 
Sentinel 
(0.819) 
rs1698268  
chr14: 84309664 Chr 14:84250124-84366454 40 FEV1/FVC LINC00911 
Sentinel 
(0.04836) 
rs72724130  
chr15: 41977690 Chr 15:41928211-42003725 3 FEV1/FVC MGA (intron) 
Sentinel 
(0.4877) 
rs12591467  
chr15: 71788387 Chr 15:71761905-71827290 20 FEV1/FVC THSD4 (intron) 
Sentinel 
(0.3553) 
rs66650179  
chr15: 84261689 Chr 15:84236689-84616675 105 FEV1/FVC SH3GL3 (intron) 
Sentinel 
(0.0299) 
rs59835752  
chr17: 28265330 Chr 17:27910546-28578639 273 FEV1/FVC EFCAB5 (intron) 
Sentinel 
(0.01471) 
rs11658500  
chr17: 36886828 Chr 17:36805562-36940540 17 FEV1/FVC CISD3 (intron) 
Sentinel 
(0.2799) 
rs6140050  
chr20: 6632901 Chr 20:6539919-6662234 24 FVC CASC20/BMP2 
Sentinel 
(0.09918) 
rs72448466  
chr20: 62363640 Chr 20:62254332-62401939 24 FEV1 ZGPAT (intron) 
Sentinel 
(0.06342) 
rs11704827  
chr22: 18450287 Chr 22:18370241-18513883 84 FEV1 MICAL3 (intron) 
Sentinel 
(0.06432) 
rs2283847  
chr22: 28181399 Chr 22:28156399-28206436 1 FEV1 LINC01422/MN1 
Sentinel (1) 
Previously-reported lung function signals 
rs2284746  
chr1: 17306675 
Chr1: 17251627-17402956 
15 
FEV1/FVC MFAP2 (intron) Sentinel 
(0.1464) 
rs62126408  
chr2: 18309132 Chr 2:18262623-18368845 11 FEV1/FVC KCNS3/RDH14 
Sentinel 
(0.1967) 
rs2571445  
chr2: 218683154 Chr 2:218642372-218720848 14 FEV1 TNS1 (exon) 
Sentinel 
(0.3905) 
rs10498230  
chr2: 229502503 Chr 2:229465307-229617415 29 FEV1/FVC SPHKAP/PID1 
Sentinel 
(0.06795) 
rs1595029  
chr3: 158241767 Chr 3:157805916-158310280 121 FVC RSRC1 (intron) 
Sentinel 
(0.03169) 
 Sentinel variant 
ID and Genomic 
position 
Locus Number of 
variants in 
credible set 
Trait Nearest genes to 
Sentinel variant 
Top ranked 
variant 
(Posterior 
probability) 
rs2045517 
chr4: 89870964 Chr 4:89725361-90102090 21 FEV1/FVC FAM13A (intron) 
rs6828137 
(0.1448) 
rs34480284  
chr4: 106064626 Chr 4:106024147-106220572 51 FEV1 LOC101929468/TET2 
Sentinel 
(0.07098) 
rs10516526 
chr4: 106688904 Chr 4:106483526-106818063 209 FEV1 GSTCD (intron) 
rs10516528 
(0.006794) 
rs34712979  
chr4: 106819053 Chr 4:106794053-106853795 1 FEV1/FVC NPNT (intron) 
Sentinel 
(0.9913) 
rs138641402  
chr4: 145445779 Chr 4:145355633-145531456 48 FEV1/FVC GYPA/HHIP-AS1 
Sentinel 
(0.09656) 
rs7715901  
chr5: 147856392 Chr 5:147811609-147881522 22 FEV1 HTR4 (intron) 
Sentinel 
(0.1958) 
rs1990950  
chr5: 156920756 Chr 5:156801152-156965873 103 FEV1/FVC ADAM19 (intron) 
Sentinel 
(0.3326) 
rs34864796 
chr6: 27459923 Chr 6:26437104-28478618 HLA FEV1 ZNF184/LINC01012 
HLA 
rs2857595 
chr6: 31568469 Chr 6:31263877-31943860 HLA FEV1/FVC NCR3/AIF1 
HLA 
rs2070600 
chr6: 32151443 Chr 6:31558841-32210605 HLA FEV1/FVC AGER (exon) 
HLA 
rs114544105 
chr6: 32635629 Chr 6:32084979-32671184 HLA FEV1 HLA-DQB1/HLA-DQA2 
HLA 
rs2768551  
chr6: 109270656 Chr 6:109168639-109295656 3 FEV1/FVC ARMC2 (intron) 
Sentinel 
(0.4661) 
rs7753012 
chr6: 142745883 Chr 6:142623056-142891387 7 FEV1/FVC GPR126 (intron) 
rs6570508 
(0.2339) 
rs148274477  
chr6: 142838173 Chr 6:142663969-142877897 5 FEV1/FVC GPR126/LOC153910 
Sentinel 
(0.5099) 
rs803923  
chr9: 119401650 Chr 9:119237495-119504774 78 FEV1/FVC ASTN2 (intron) 
Sentinel 
(0.03569) 
rs10858246  
chr9: 139102831 Chr 9:139057491-139135654 13 FVC QSOX2 (intron) 
Sentinel 
(0.1345) 
rs7090277  
chr10: 12278021 Chr 10:12216815-12334390 31 FEV1/FVC CDC123 (intron) 
Sentinel 
(0.1363) 
rs2637254  
chr10: 78312002 Chr 10:78180071-78608611 224 FEV1 C10orf11 (intron) 
Sentinel 
(0.01745) 
rs2348418  
chr12: 28689514 Chr 12:28237880-28764845 152 FVC CCDC91 (intron) 
Sentinel 
(0.05737) 
rs12820313  
chr12: 96255704 Chr 12:96180161-96308432 26 FEV1/FVC SNRPF (intron) 
Sentinel 
(0.2313) 
rs10851839  
chr15: 71628370 Chr 15:71562373-71673497 15 FEV1/FVC THSD4 (intron) 
Sentinel 
(0.5145) 
rs3743609  
chr16: 75467021 Chr 16:75279623-75541739 270 FEV1/FVC CFDP1 (intron) 
Sentinel 
(0.01521) 
rs35524223  
chr17: 44192590 Chr 17:43435181-44890603 279 FEV1 KANSL1 (intron) 
Sentinel 
(0.01611) 
rs7218675 
chr17: 73513185 Chr 17:73460781-73552560 34 FEV1 TSEN54 (intron) 
rs146301005 
(0.05408) 
rs2834440  
chr21: 35690499 Chr 21:35628304-35742962 48 FEV1/FVC LINC00310/KCNE2 
Sentinel 
(0.1445) 
  
 Supplementary Table 6: Association results for the 6 previously reported MHC region GWAS signals 
before and after conditioning on HLA-DQβ1 amino acid position 57. Unconditional P values and 
standard errors are Genomic Control corrected. P values in bold meet genome-wide significance (P<5x10
-8
). 
a) FEV1 
  FEV1 
FEV1 (conditioned on HLA-DQβ1 
amino acid position 57) 
MHC signal Chr:pos beta se P beta se P 
rs34864796 
(ZKSCAN3) 
6:27459923 -0.074 0.010 6.14E-14 -0.058 0.010 1.26E-09 
rs28986170* 
(LST1) 
6:31556155 0.056 0.013 3.07E-05 0.042 0.013 1.74E-03 
rs2857595 (NCR3) 6:31568469 -0.039 0.008 2.05E-06 -0.023 0.008 3.52E-03 
rs2070600 (AGER) 6:32151443 0.039 0.014 4.15E-03 0.023 0.013 7.32E-02 
rs114544105 
(HLA-DQB1) 
6:32635629 -0.049 0.008 8.84E-11 -0.006 0.007 4.04E-01 
rs114229351† 
(HLA-DQB1) 
6:32648418 -0.046 0.009 1.15E-07 -0.015 0.009 7.75E-02 
b) FEV1/FVC 
  FEV1/FVC 
FEV1/FVC (conditioned on HLA-DQβ1 
amino acid position 57) 
MHC signal Chr:pos beta se P beta se P 
rs34864796 
(ZKSCAN3) 
6:27459923 -0.062 0.010 3.52E-10 -0.041 0.010 2.07E-05 
rs28986170* 
(LST1) 
6:31556155 0.077 0.013 1.23E-08 0.065 0.013 1.11E-06 
rs2857595 (NCR3) 6:31568469 -0.048 0.008 3.50E-09 -0.028 0.008 4.27E-04 
rs2070600 (AGER) 6:32151443 0.140 0.014 3.11E-25 0.120 0.013 4.23E-20 
rs114544105 
(HLA-DQB1) 
6:32635629 -0.063 0.008 5.20E-17 -0.008 0.007 2.96E-01 
rs114229351† 
(HLA-DQB1) 
6:32648418 -0.050 0.009 6.79E-09 -0.006 0.009 5.20E-01 
*Already conditioned on rs2070600 & rs201002132. 
†Already conditioned on rs34864796. 
 
 Supplementary Table 7: GRASP and/or GWAS Catalog-reported genome-wide associations for the 97 
lung function signals. *Where signals for which a credible set was not defined, variants within 2Mb and 
LD r
2≥0.8 were used to query the databases. The previously reported signals of association with COPD and 
lung function are not shown. For signals associated with height, the consistency of direction of effect on 
lung function with height is indicated for all 3 traits (FEV1, FVC, FEV1/FVC), where “+” indicates that the 
allele associated with increased height is also associated with an increase in the lung function trait and “-” 
indicates that the allele associated with increased height is associated with decreased lung function. 
Trait 
Sentinel lung function 
association  SNP Locus name GWAS catalog/GRASP reported trait(s) 
Novel signals 
FEV1 
FVC  
rs17513135 
chr1:40035686 LOC101929516 
HDL cholesterol, C-reactive protein levels, Mean 
corpuscular hemoglobin, Triglycerides 
FEV1 
FVC 
rs1192404 
chr1: 92068967 CDC7-TGFBR3 
Optic disc area, Vertical cup disc ratio, PC2 (Disc 
area), FAC2 (Disc area, cup shape measure, and 
oppositely directed rim to disc area ratio and 
linear cup to disc ratio) 
FVC 
rs200154334 
chr1:118862070 SPAG17-TBX15 
Height (---), Infant length, Height tails (upper and 
lower 5th percentiles) 
FEV1 
FVC 
rs61332075 
chr2:239316560 
TRAF3IP1-
ASB1 Iris furrow contractions 
FEV1 
FVC 
rs13110699 
chr4: 89815695 FAM13A 
Fibrotic idiopathic interstitial pneumonias 
(pulmonary fibrosis) 
FEV1 
FVC 
rs7713065 
chr5: 131788334 C5orf56 
Juvenile idiopathic arthritis (including 
oligoarticular and rheumatoid factor negative 
polyarticular JIA), Crohn's disease 
FEV1 
FVC 
rs10515750 
chr5: 156810072 CYFIP2 
Bipolar disorder and schizophrenia, Bipolar 
disorder (body mass index interaction), Several 
serum metabolites 
FVC 
rs10870202 
chr9: 139257411 DNLZ 
Inflammatory bowel disease (Crohn's disease & 
Ulcerative colitis), IgA nephropathy 
FVC 
rs7095607 
chr10: 69957350 MYPN Height (---) 
FEV1 
rs1494502 
chr12: 65824670 MSRB3 Temperament 
FEV1 
FVC 
rs66650179 
chr15: 84261689 SH3GL3 Height (+++) 
FEV1 
FVC 
rs59835752 
chr17: 28265330 EFCAB5 
Coffee consumption (cups per day), Psoriasis 
(HLA-C risk allele negative) 
FVC 
rs6140050 
chr20: 6632901 CASC20-BMP2 
Height (--+), Waist to hip ratio adjusted for body 
mass index, Sitting height ratio 
FEV1 
rs72448466 
chr20: 62363640 ZGPAT 
Inflammatory bowel disease (Crohn's disease & 
Ulcerative colitis), Prostate cancer, Atopic 
dermatitis 
FEV1 
rs11704827 
chr22: 18450287 MICAL3 
Liver enzyme levels (gamma glutamyl 
transferase), Presence of antiphospholipid 
antibodies 
Previously-reported lung function signals 
FEV1 
FVC 
rs2284746 
chr1:17306675 MFAP2 
Height (adults, males and females) (-+-), Height 
tails (upper and lower 5th percentiles) 
FEV1 rs993925* MIR548F3 Acne (severe) 
 Trait 
Sentinel lung function 
association  SNP Locus name GWAS catalog/GRASP reported trait(s) 
FVC chr1: 218860068 
FVC 
rs1595029 
chr3: 158241767 RSRC1 
Height (+++), Height tails (upper and lower 5th 
percentiles) 
FEV1 
FVC 
rs2045517 
chr4: 89870964 FAM13A 
Fibrotic idiopathic interstitial pneumonias 
(pulmonary fibrosis) 
FEV1 
rs34480284 
chr4: 106064626 TET2 Prostate cancer 
FEV1 
rs34864796* 
chr6: 27459923 
ZNF184-
LINC01012 Schizophrenia, Bipolar disorder 
FEV1 
FVC 
rs2857595* 
chr6: 31568469 NCR3-AIF1 
Type 1 Diabetes, Laryngeal squamous cell 
carcinoma 
FEV1 
FVC 
rs7753012 
chr6: 142745883 GPR126 Height (---), Scoliosis 
FEV1 
FVC 
rs803923 
chr9: 119401650 ASTN2 Hippocampal volume 
FEV1 
FVC 
rs11172113* 
chr12: 57527283 LRP1 Cervical artery dissection, Migraine 
FEV1 
rs7155279* 
chr14: 92485881 TRIP11 Height (---) 
FEV1 
rs117068593* 
chr14: 93118229 RIN3 
Bone mineral density (lower limb and total body 
less head), Paget's disease 
FEV1 
rs35524223 
chr17: 44192590 KANSL1 
Parkinson's disease, Intracranial volume, Male 
pattern baldness, Subcortical brain region 
volumes, Ovarian cancer in BRCA1 mutation 
carriers, Epithelial ovarian cancer, Progressive 
supranuclear palsy, Hematocrit (Hct), Hemoglobin 
(Hb), Primary biliary cirrhosis, Fibrotic idiopathic 
interstitial pneumonias (pulmonary fibrosis) 
FEV1 
FVC 
rs2834440 
chr21: 35690499 KCNE2 Height (+-+), BMI 
  
  
Supplementary Table 8: Look up for association with smoking behaviour for the 97 lung function 
variants. Smoking association results from a previously-reported study which compared 24,457 heavy-
smokers vs. 24,474 never-smokers in UK BiLEVE
46
. One variant shows evidence of association with 
smoking behaviour using a 5% Bonferroni-corrected threshold for 97 tests (P < 5.15x10
-4
, shown in bold). P 
values for smoking association are genomic-control corrected (λ=1.101) except where the association is 
conditioned on another variant. For the 5 novel variants with P<0.05 (*), a further look-up was undertaken 
in results from the TAG consortium study of smoking behaviour (PMID:20418890). Four traits were 
analysed: cigarettes per day, likelihood of smoking initiation, likelihood of quitting smoking and (log) age of 
onset. Associations (P<0.05) with smoking-related traits were observed for; rs72448466 (P=0.01, likelihood 
of quitting) and rs113745635 (P=0.02, age of onset of smoking). Both associations had a consistent direction 
of effect to that shown in the table below.  
trait rsid 
Position 
b37 Gene 
Coded 
Allele 
Conditioned 
on 
Smoking 
OR (95% C.I.) 
Smoking 
P 
43 novel variants 
FEV1 
FVC 
rs17513135 1:40035686 LOC101929516 T 
 
0.99 (0.96,1.03) 0.708 
FEV1 
FVC 
rs1192404 1:92068967 TGFBR3 G 
rs12140637 
1.03 (1.00,1.07) 0.053 
FEV1 
FVC 
rs12140637 1:92374517 TGFBR3 T 
 
1.00 (0.97,1.03) 0.897 
FVC rs200154334 1:118862070 SPAG17 C  1.00 (0.97,1.03) 0.913 
FEV1 
FVC 
rs6688537 1:239850588 CHRM3 A 
 
0.99 (0.96,1.02) 0.417 
FEV1 
FVC 
rs61332075 2:239316560 TRAF3IP1 C 
 
1.01 (0.97,1.05) 0.627 
FEV1 
FVC 
rs1458979 3:55150677 CACNA2D3 G 
 
0.98 (0.96,1.01) 0.243 
FVC rs1490265 3:67452043 SUCLG2 A  0.98 (0.95,1.01) 0.204 
FEV1 
FVC 
rs2811415 3:127991527 EEFSEC G 
 
1.01 (0.97,1.05) 0.609 
FEV1 
FVC 
esv2660202 3:168738454 MECOM C 
 
0.97 (0.94,1.00) 0.021* 
FEV1 
FVC 
rs13110699 4:89815695 FAM13A G 
rs2045517 
1.00 (0.97,1.04) 0.813 
FVC rs91731 5:33334312 TARS A  0.99 (0.95,1.04) 0.791 
FEV1 
FVC 
rs1551943 5:52195033 ITGA1 A 
 
1.01 (0.97,1.04) 0.746 
FVC rs2441026 5:53444498 ARL15 T  1.01 (0.99,1.04) 0.297 
FEV1 
FVC 
rs7713065 5:131788334 C5orf56 C 
 
1.03 (1.00,1.07) 0.029* 
FEV1 rs3839234 5:148596693 ABLIM3 T  1.00 (0.98,1.03) 0.781 
FEV1 
FVC 
rs10515750 5:156810072 CYFIP2 T 
rs1990950 
0.98 (0.93,1.03) 0.450 
FEV1 
FVC 
rs28986170 6:31556155 LST1 AA 
rs2070600 
rs201002132 
1.00 (0.94,1.05) 0.889 
FEV1 rs114229351 6:32648418 HLA-DQB1 C rs34864796 0.97 (0.94,1.01) 0.112 
FEV1 
FVC 
rs141651520 6:73670095 KCNQ5 A 
 
1.00 (0.97,1.04) 0.852 
FEV1 
FVC 
rs10246303 7:7286445 C1GALT1 T 
 
1.01 (0.98,1.04) 0.580 
FEV1 
FVC 
rs72615157 7:99635967 ZKSCAN1 A 
 
1.02 (0.98,1.05) 0.371 
FEV1 rs12698403 7:156127246 LOC285889 A  0.98 (0.96,1.01) 0.224 
FEV1 rs7872188 9:4124377 GLIS3 T  0.99 (0.96,1.02) 0.463 
 trait rsid 
Position 
b37 Gene 
Coded 
Allele 
Conditioned 
on 
Smoking 
OR (95% C.I.) 
Smoking 
P 
FVC rs10870202 9:139257411 DNLZ C rs10858246 0.99 (0.97,1.02) 0.453 
FEV1 
FVC 
rs3847402 10:30267810 KIAA1462 A 
 
1.02 (0.99,1.05) 0.124 
FVC rs7095607 10:69957350 MYPN A  1.00 (0.98,1.03) 0.881 
FEV1 rs2509961 11:62310909 AHNAK C  1.00 (0.98,1.03) 0.770 
FEV1 rs11234757 11:86443072 PRSS23 A  1.00 (0.96,1.04) 0.972 
FEV1 rs567508 11:126008910 RPUSD4 A  1.01 (0.97,1.05) 0.645 
FEV1 rs1494502 12:65824670 MSRB3 G  1.01 (0.98,1.04) 0.566 
FEV1 
FVC 
rs113745635 12:95554771 FGD6 T 
 
0.97 (0.94,1.00) 0.041* 
FVC rs35506 12:115500691 TBX3 A  0.99 (0.96,1.02) 0.577 
FEV1 
FVC 
rs1698268 14:84309664 LINC00911 T 
 
1.00 (0.97,1.03) 0.894 
FEV1 
FVC 
rs72724130 15:41977690 MGA T 
 
1.04 (0.98,1.10) 0.224 
FEV1 
FVC 
rs12591467 15:71788387 THSD4 T 
rs10851839 
1.00 (0.97,1.02) 0.860 
FEV1 
FVC 
rs66650179 15:84261689 SH3GL3 C 
 
0.99 (0.96,1.03) 0.637 
FEV1 
FVC 
rs59835752 17:28265330 EFCAB5 T 
 
1.00 (0.97,1.02) 0.777 
FEV1 
FVC 
rs11658500 17:36886828 CISD3 A 
 
1.00 (0.96,1.03) 0.861 
FVC rs6140050 20:6632901 BMP2 A  1.00 (0.97,1.03) 0.951 
FEV1 rs72448466 20:62363640 ZGPAT C  1.03 (1.00,1.06) 0.047* 
FEV1 rs11704827 22:18450287 MICAL3 T  0.99 (0.96,1.03) 0.751 
FEV1 rs2283847 22:28181399 MN1 T  0.97 (0.95,1.00) 0.048* 
54 previously-reported variants 
FEV1 
FVC 
rs2284746 1:17306675 MFAP2 G 
 
1.00 (0.97,1.02) 0.885 
FEV1 rs6681426 1:150586971 ENSA A  1.00 (0.97,1.02) 0.816 
FEV1 
FVC 
rs993925 1:218860068 TGFB2 T 
 
1.02 (1.00,1.05) 0.082 
FEV1 
FVC 
rs4328080 1:219963088 RNU5F-1 A 
 
1.04 (1.02,1.07) 0.002 
FEV1 
FVC 
rs62126408 2:18309132 KCNS3 C 
 
0.98 (0.95,1.02) 0.340 
FVC rs1430193 2:56120853 EFEMP1 T  1.00 (0.97,1.03) 0.910 
FEV1 rs2571445 2:218683154 TNS1 G  1.00 (0.97,1.02) 0.747 
FEV1 
FVC 
rs10498230 2:229502503 PID1 T 
 
1.05 (1.00,1.11) 0.040 
FEV1 
FVC 
rs12477314 2:239877148 HDAC4 T 
 
1.01 (0.98,1.05) 0.511 
FEV1 
FVC 
rs1529672 3:25520582 RARB A 
 
0.98 (0.95,1.01) 0.244 
FVC rs1595029 3:158241767 RP11-538P18.2 C  0.98 (0.96,1.01) 0.158 
FEV1 rs1344555 3:169300219 MECOM T  1.02 (0.98,1.05) 0.321 
FEV1 
FVC 
rs2045517 4:89870964 FAM13A T 
 
1.03 (1.01,1.06) 0.018 
FEV1 rs34480284 4:106064626 TET2 TA  1.02 (1.00,1.05) 0.091 
FEV1 rs10516526 4:106688904 GSTCD G  1.00 (0.95,1.05) 0.954 
FEV1 
FVC 
rs34712979 4:106819053 NPNT A 
 
0.98 (0.95,1.01) 0.239 
 trait rsid 
Position 
b37 Gene 
Coded 
Allele 
Conditioned 
on 
Smoking 
OR (95% C.I.) 
Smoking 
P 
FEV1 
FVC 
rs138641402 4:145445779 HHIP T 
 
1.01 (0.98,1.04) 0.420 
FEV1 
FVC 
rs153916 5:95036700 SPATA9 T 
 
0.99 (0.96,1.02) 0.470 
FEV1 rs7715901 5:147856392 HTR4 G  1.00 (0.98,1.03) 0.843 
FEV1 
FVC 
rs1990950 5:156920756 ADAM19 T 
 
1.01 (0.99,1.04) 0.340 
FVC rs6924424 6:7801611 BMP6 G  0.99 (0.96,1.03) 0.657 
FEV1 rs34864796 6:27459923 ZKSCAN3 A  0.96 (0.92,1.00) 0.034 
FEV1 
FVC 
rs2857595 6:31568469 NCR3 A 
 
1.00 (0.97,1.04) 0.833 
FEV1 
FVC 
rs2070600 6:32151443 AGER T 
 
0.97 (0.92,1.03) 0.297 
FEV1 rs114544105 6:32635629 HLA-DQB1 A  0.99 (0.96,1.02) 0.484 
FEV1 
FVC 
rs2768551 6:109270656 ARMC2 A 
 
0.96 (0.93,1.00) 0.032 
FEV1 
FVC 
rs7753012 6:142745883 LOC153910 G 
 
1.00 (0.97,1.03) 0.973 
FEV1 
FVC 
rs148274477 6:142838173 GPR126 T 
 
0.93 (0.86,1.02) 0.111 
FEV1 
FVC 
rs16909859 9:98204792 PTCH1 A 
 
1.02 (0.97,1.07) 0.467 
FEV1 
FVC 
rs803923 9:119401650 ASTN2 A 
 
1.02 (0.99,1.05) 0.143 
FVC rs10858246 9:139102831 LHX3 C  0.99 (0.96,1.02) 0.378 
FEV1 
FVC 
rs7090277 10:12278021 CDC123 A 
 
1.00 (0.98,1.03) 0.717 
FEV1 rs2637254 10:78312002 C10orf11 A  1.00 (0.98,1.03) 0.712 
FVC rs4237643 11:43648368 HSD17B12 G  0.99 (0.97,1.02) 0.641 
FVC rs2863171 11:45250732 PRDM11 C  1.04 (1.00,1.08) 0.036 
FVC rs2348418 12:28689514 CCDC91 C  1.02 (0.99,1.04) 0.235 
FEV1 
FVC 
rs11172113 12:57527283 LRP1 C 
 
1.01 (0.98,1.03) 0.695 
FEV1 
FVC 
rs12820313 12:96255704 CCDC38 C 
 
1.02 (0.99,1.06) 0.142 
FEV1 rs569058293 12:114743533 RBM19 C  1.73 (1.17,2.55) 0.006 
FEV1 rs10850377 12:115201436 TBX3 A  0.98 (0.95,1.01) 0.172 
FEV1 rs7155279 14:92485881 TRIP11 T  1.02 (0.99,1.04) 0.286 
FEV1 rs117068593 14:93118229 RIN3 T  1.00 (0.96,1.03) 0.857 
FEV1 
FVC 
rs10851839 15:71628370 THSD4 A 
 
1.01 (0.99,1.04) 0.350 
FEV1 
FVC 
rs12149828 16:10706328 TEKT5 A 
 
0.98 (0.95,1.02) 0.376 
FEV1 
FVC 
rs12447804 16:58075282 MMP15 T 
 
0.97 (0.94,1.01) 0.112 
FEV1 
FVC 
rs3743609 16:75467021 CFDP1 C 
 
1.00 (0.98,1.03) 0.819 
FVC rs1079572 16:78187138 WWOX A  1.00 (0.98,1.03) 0.843 
FEV1 rs35524223 17:44192590 KANSL1 A  0.94 (0.91,0.97) 4.79E-04 
FVC rs6501431 17:68976415 KCNJ2 T  1.00 (0.97,1.03) 0.930 
FEV1 rs7218675 17:73513185 TSEN54 A  1.00 (0.97,1.03) 0.839 
FEV1 
FVC 
rs113473882 19:41124155 LTBP4 C 
 
0.86 (0.75,0.99) 0.033 
FEV1 rs2834440 21:35690499 KCNE2 A  0.98 (0.95,1.00) 0.091 
 trait rsid 
Position 
b37 Gene 
Coded 
Allele 
Conditioned 
on 
Smoking 
OR (95% C.I.) 
Smoking 
P 
FVC 
FEV1 rs134041 22:28056338 MN1 C  0.99 (0.97,1.02) 0.598 
FEV1 
FVC 
rs7050036 X:15964845 AP1S2 A 
 
1.00 (0.98,1.02) 0.971 
 
  
  
Supplementary Table 9: Summary of the number of variants analysed and the standard deviation of 
the COPD risk score in each of the studies included in risk score and single variant analyses of COPD 
susceptibility and risk of COPD exacerbations. 
Study 
Number of variants 
total 
Number of 
proxies 
Number of variants in risk 
score 
Standard deviation of COPD 
risk score 
European ancestry 
BioMe 94 1 93 6.12 
DiscovEHR 93 7 86 5.80 
COPDGene 92 3 90 5.84 
ECLIPSE 91 2 90 5.83 
NETT/NAS 91 2 90 5.79 
GenKOLS 91 2 90 5.84 
Groningen 93 3 93 5.70 
Laval 93 2 93 5.75 
UBC 93 3 93 5.66 
LHS 89 0 89 
 deCODE 
COPD 95 3 95 5.85 
UK Biobank 95 3 95 6.09 
Chinese ancestry 
CKB 71 49 70 4.63 
 
  
 Supplementary Table 10: Single variant results for association with COPD risk. Results for COPD risk associations are provided for 
variants representing 95 lung-function-associated signals that could be followed up in case-control studies. The 47 variants for which UK 
BiLEVE data did not contribute to discovery are presented in (a), and the results for the 48 variants for which UK BiLEVE data did contribute to 
discovery are presented in (b). When the sentinel variant (Sentinel rsid) was not available in a study, a proxy (Proxy rsid) was analysed instead. 
For signals where different variants were analysed across studies we present results for the variants analysed in the largest number of COPD 
cases. Studies were clustered into 3 groups according to their study design and phenotype classification criteria: electronic health medical record 
(eMR), which included BioMe and DiscovEHR; COPD case-control studies, which included COPDGene Study, ECLIPSE, NETT/NAS and the 
Norway GenKOLS study; and lung resection studies, which included Groningen, Laval and UBC. Overall sample sizes are given as N effective 
sample sizes (the sum of the products of the total sample size and imputation quality within each study). Results in the China Kadoorie Biobank 
prospective cohort (CKB) are presented in table (c). The coded allele presented in the tables is always the risk allele (defined as the allele 
associated with decreased lung function in UK BiLEVE). Odds ratios are bold in table (a) if directions of effect are consistent for lung function 
and COPD i.e. the same allele is associated both with decreased lung function and a higher risk of COPD. P values after meta-analysing all 
studies of European descent which reached a Bonferroni corrected threshold for 95 tests (5.26x10
-4
) are presented in bold in table (a). In table 
(c), P values which reached a Bonferroni corrected threshold for 71 tests (7.04x10
-4
) in CKB are indicated in bold. In table (c): *Consistency of 
direction of effect unavailable (“-“) if OR=1 in either European Ancestry results or in CKB. 
 
 
See accompanying Excel file. 
  
Supplementary Table 11: Association of COPD risk with lung function risk score. Studies are grouped according to their study design and phenotyping: 
“eMR”, electronic medical records, which used ICD codes to define COPD (DiscovEHR also used spirometry to refine the COPD definition); “case-control”, 
COPD case-control, which used post-bronchodilator spirometry to define COPD; “lung resection cohort”, which used a combination of pre and post-
bronchodilator spirometry to define COPD; the Icelandic Biobank, deCODE, where cases were selected from a population based study and a study of COPD 
patients and defined using a spirometric definition, controls were selected as individuals within the cohort that were not known cases (no spirometric definition 
was used for controls); and UK Biobank, which used spirometry to define both COPD cases and controls. UK Biobank is separated into UK BiLEVE, which 
was the discovery population for 48 of the variants included in the risk score (43 discovered in this analysis and 5 in 
46
) and the remaining of UK Biobank 
labelled “UK Biobank”. Meta-analysed results within each of these groups and across all studies are presented, both per allele and as per standard deviation of 
the risk score (~6 alleles). 
Study/ Study group 
per allele per sd 
N cases N controls 
OR (95% CI) P OR (95% CI) P 
European ancestry  
eMR 1.01 (1,1.02) 5.56E-03 1.08 (1.02,1.14) 5.55E-03 1471 14849 
COPD case control 1.05 (1.05,1.06) 5.52E-36 1.36 (1.3,1.43) 5.65E-36 5778 3950 
lung resection 1.05 (1.02,1.08) 6.56E-04 1.33 (1.13,1.57) 6.74E-04 310 332 
deCODE COPD 1.03 (1.02,1.04) 7.67E-09 1.18 (1.12,1.25) 7.67E-09 1248 74770 
UK BiLEVE 1.06 (1.06,1.07) 5.03E-193 1.46 (1.42,1.50) 5.03E-193 9563 27387 
UK Biobank 1.04 (1.03,1.05) 1.96E-12 1.27 (1.19,1.36) 1.96E-12 984 26561 
UK BILEVE + UK Biobank 1.06 (1.06,1.06) 3.94E-205 1.42 (1.39,1.45) 3.94E-205 10547 53948 
All 1.05 (1.05,1.05) 1.59E-223 1.35 (1.32,1.37) 1.59E-223 19354 147849 
All excluding UK BiLEVE 1.04 (1.03,1.04) 5.05E-49 1.24 (1.20,1.27) 5.05E-49 9791 120462 
Chinese ancestry  
CKB 1.02 (1.01,1.02) 4.22E-06 1.077 (1.044,1.112) 4.22E-06 7116 20919 
 
  
 Supplementary Table 12: Single variant results for association with COPD exacerbations. Results for COPD exacerbations associations are provided for 
95 lung-function-associated signals that could be followed up in case-control studies. When the sentinel variant (Sentinel rsid) was not available in a study, a 
proxy (Proxy rsid) was analysed instead. For signals where different variants were analysed across studies we present results for the variants analysed in the 
largest number of COPD cases. Studies were clustered into 2 groups according to their study design and phenotype classification criteria: electronic health 
medical record (eMR), which included BioMe and DiscovEHR; and COPD case-control studies, which included COPDGene Study, ECLIPSE, NETT/NAS and 
the Norway GenKOLS study. Meta-analysed results within each of these groups, as well as for LHS and UK Biobank, and across all studies are presented in 
table (a). Results in the China Kadoorie Biobank prospective cohort (CKB) are presented in table (b). The coded allele presented in the tables is always the risk 
allele (defined as the allele associated with decreased lung function in UK BiLEVE). 
 
See accompanying Excel file. 
  
  
Supplementary Table 13: Association of COPD exacerbations with lung function risk score. Results 
for COPD exacerbation risk score associations are provided. Studies that took part in these analyses were 
grouped according to their study design and phenotyping into: electronic health medical record (eMR), 
which included BioMe and DiscovEHR and COPD case-control studies, which included COPDGene Study, 
ECLIPSE, NETT/NAS and the Norway GenKOLS study. Meta-analysed results within each of these groups 
and across all studies are presented per allele. 
Study/ Study group 
per allele 
N cases N controls 
OR (95% CI) P 
European ancestry 
eMR 0.99 (0.97,1.01) 4.74E-01 773 664 
COPD case control 1.01 (0.99,1.02) 3.41E-01 1042 4724 
LHS 0.97 (0.94,1.01) 1.31E-01 100 4002 
UK Biobank 1 (0.99,1.02) 5.61E-01 647 9900 
All 1 (0.99,1.01) 7.25E-01 2562 19290 
      
 
  
Chinese ancestry 
CKB 1 (0.99,1.02) 7.35E-01 5292 1824 
 
  
 Supplementary Table 14: Deleterious variants that explain the lung function association signal. Each 
of the 97 sentinel variants were conditioned on nearby coding functional variants as identified by Variant 
Effect Predictor. The unconditional association effect sizes and P values are shown for the sentinel variant 
with the conditional effect sizes and P values for the sentinel after conditioning on the functional variant 
shown in the consecutive rows. The LD of each functional variant with the sentinel is shown (r
2
 with 
sentinel), the Combined Annotation Dependent Depletion (CADD), PHRED-scaled score and the gene 
implicated by the functional variant. Only sentinels and functional conditional variants are shown where 
P>0.01 after conditioning. 
*Sentinel rs28986170 is a tertiary signal after conditioning on rs2070600 and rs201002132 and hence was 
conditioned on these in addition to any functional variants. 
trait 
Sentinel/ 
condition on rsid position 
r
2
 with 
sentinel 
CADD 
PHRED 
Beta (se) 
sentinel 
unconditional 
conditional 
P sentinel 
unconditional 
conditional Gene 
Novel variants 
FEV1 sentinel rs28986170* 6:31556155   0.077 (0.013) 1.23E-08  
FVC  condition rs41558312 6:31378864 0.688 12.3 0.033 (0.013) 0.013 MICA 
  condition rs41293883 6:31474820 0.757 12.5 0.030 (0.013) 0.025 MICB 
FVC sentinel rs7095607 10:69957350   -0.037 (0.007) 3.92E-08  
 condition rs7079481 10:69957350 0.993 27.0 0.000 (0.006) 0.947 MYPN 
FEV1 sentinel rs2509961 11:62310909    0.036 (0.007) 1.69E-07  
 condition rs13941 11:62310909 0.454 10.0 0.016 (0.007) 0.017 C11orf83 
FEV1 sentinel rs11658500 17:36886828    -0.051 (0.009) 4.69E-08  
FVC condition rs2879097 17:36886828 0.501 19.2 -0.021 (0.009) 0.024 CISD3 
Previously-reported variants 
FEV1 sentinel rs2571445 2:218683154   0.043 (0.007) 2.19E-10  
 condition rs1063281 2:218668732 0.925 17.99 0.005 (0.007) 0.410 TNS1 
FEV1 sentinel rs34864796 6:27459923   -0.075 (0.010) 6.14E-14  
 condition rs34788973 6:27459923 0.797 6.853 -0.010 (0.010) 0.277 OR2B2 
FEV1 sentinel rs2857595 6:31568469   -0.048 (0.008) 3.50E-09  
FVC condition rs3134900 6:31473957 0.580 8.773 -0.013 (0.008) 0.100 MICB 
FEV1 sentinel rs114544105 6:32635629   -0.049 (0.008) 8.84E-11  
 condition rs3891176 6:32634318 0.971 13.75 -0.005 (0.007) 0.516 HLA-DQB1 
FEV1 sentinel rs35524223 17:44192590   -0.061 (0.008) 1.13E-13  
 condition rs34579536 17:44108906 0.968 3.452 -0.005 (0.008) 0.508 KANSL1 
 condition rs17651549 17:44061278 0.981 18.18 -0.004 (0.008) 0.647 MAPT 
 condition rs12373123 17:43924073 0.977 17.99 -0.005 (0.008) 0.552 SPPL2C 
FEV1 sentinel rs7218675 17:73513185   -0.035 (0.007) 2.34E-06  
 condition rs991150 17:73513185 0.991 13.19 0.000 (0.007) 0.961 TSEN54 
FEV1 sentinel rs113473882 19:41124155    0.145 (0.035) 3.03E-05  
FVC condition rs34093919 19:41117300 0.878 18.35 -0.011 (0.034) 0.742 LTBP4 
  
 Supplementary Table 15: Plausible genes per locus. Summary of general and functional information with 
regards to each novel and previously-reported sentinel variant (where applicable). All plausible genes (for 
definition, see ‘Implication of causal genes’ section, Online Methods) with regards to each loci are 
presented. Non-high-priority genes at the HLA regions are excluded. *High-priority genes. #Variant did not 
reach P<5.15x10
-4
 in this study for any trait. 
Genome-wide 
significant trait 
(additional traits with 
P<5.15x10-4) 
Variant ID (position b37) Nearest gene(s) All plausible genes 
Novel signals 
FEV1/FVC (FVC) rs17513135 (chr1:40,035,686) LOC101929516 
(intron) 
PABPC4*, OXCT2, 
MACF1, HPCAL4, 
NDUFS5, BMP8A 
FEV1/FVC (-) rs1192404 (chr1:92,068,967) CDC7/TGFBR3 CDC7 
FEV1/FVC (FEV1) rs6688537 (chr1:239,850,588) CHRM3 (intron) CHRM3* 
FEV1/FVC (-) rs61332075 (chr2:239,316,560) TRAF3IP1/ASB1 ASB1, TRAF3IP1 
FVC (FEV1) rs1490265 (chr3:67,452,043) SUCLG2 (intron) SUCLG2 
FEV1/FVC (FEV1) rs2811415 (chr3:127,991,527) EEFSEC (intron) RUVBL1*, SEC61A1, 
EEFSEC 
FEV1/FVC (-) rs13110699 (chr4:89,815,695) FAM13A (intron) FAM13A* 
FEV1/FVC (-) rs1551943 (chr5:52,195,033) ITGA1 (intron) ITGA1 
FEV1/FVC (-) rs7713065 (chr5:131,788,334) C5orf56 (intron) SLC22A4, SLC22A5,  
RAD50, IRF1, PDLIM4,  
P4HA2 
FEV1 (FVC, FEV1/FVC) rs3839234 (chr5:148,596,693) ABLIM3 (intron) GRPEL2*, ABLIM3*, 
AFAP1L1 
FEV1/FVC (FEV1) rs10515750 (chr5:156,810,072) CYFIP2 (intron) ADAM19*, ITK, FNDC9, 
NIPAL4, CYFIP2 
FEV1/FVC (FEV1) rs200003338 (chr6:31,556,155) LST1 (intron) MICB*, MICA* 
FEV1/FVC (FEV1) rs10246303 (chr7:7,286,445) C1GALT1 (3’ UTR) C1GALT1* 
FEV1/FVC (-) rs72615157 (chr7:99,635,967) ZKSCAN1 (3’ UTR) PILRB, TRIM4, AP4M1,  
PVRIG, COPS6, MCM7,  
STAG3, CNPY4, ZNF3,  
LAMTOR4, ZSCAN21,  
MEPCE, ZCWPW1, TAF6, 
TSC22D4, MBLAC1, 
NYAP1, GAL3ST4, 
ZKSCAN1, PILRA 
FVC (FEV1) rs10870202 (chr9:139,257,411) DNLZ (intron) INPP5E*, CARD9*, 
SNAPC4, DNLZ,  
SDCCAG3, GPSM1,  
PMPCA, SEC16A 
FVC (FEV1) rs7095607 (chr10:69,957,350) MYPN (intron) MYPN*, ATOH7 
FEV1 (FVC) rs2509961 (chr11:62,310,909) AHNAK (intron) ROM1*, EML3*, MTA2*, 
GANAB*, C11orf83*, 
INTS5, BSCL2, ZBTB3,  
AHNAK, B3GAT3,  
TTC9C, HNRNPUL2,  
UBXN1 
FEV1 (FVC, FEV1/FVC)
 rs567508 (chr11:126,008,910) RPUSD4/CDON FOXRED1, RPUSD4,  
CDON 
FEV1 (FVC) rs1494502 (chr12:65,824,670) MSRB3 (intron) LEMD3 
FEV1/FVC (FEV1) rs113745635 (chr12: 95,554,771) FGD6 (intron) FGD6, VEZT, NDUFA12,  
 NR2C1, SNRPF 
FEV1/FVC (-) rs72724130 (chr15:41,977,690) MGA (intron) SPTBN5, MAPKBP1 
FEV1/FVC (FEV1) rs66650179 (chr15:84,261,689) SH3GL3 (intron) ADAMTSL3 
FEV1/FVC (-) rs59835752 (chr17: 28,265,330) EFCAB5 (intron) EFCAB5*, CRYBA1*, 
SSH2*, SLC6A4*, CPD, 
GOSR1, NSRP1, CORO6, 
ANKRD13B, GIT1, 
BLMH, TP53I13 
FEV1/FVC (FEV1) rs11658500 (chr17:36,886,828) CISD3 (intron) CISD3*, PCGF2 
FEV1 (FVC) rs72448466 (chr20:62,363,640) ZGPAT (intron) LIME1*, ZGPAT, RTEL1, 
EEF1A2, SLC2A4RG, 
STMN3 
FEV1 (FVC) rs11704827 (chr22:18,450,287) MICAL3 (intron) MICAL3 
Previously-reported lung function signals 
FEV1 (FVC) rs2284746 (chr1:17,306,675) MFAP2 (intron) MFAP2, PADI2,  
ATP13A2, CROCC, 
NBPF1, MACF1, SDHB 
FEV1 (FVC) rs6681426 (chr1:150,586,971) MCL1/ENSA GOLPH3L* , FAM63A, 
ADAMTSL4, MRPS21, 
LASS2, HORMAD1, 
ARNT, CTSK, CTSS, 
CDC42SE1, BNIPL, 
C1orf138, MCL1, 
SETDB1, SCNM1, ANXA9 
FEV1/FVC (-) rs993925 (chr1:218,860,068) MIR548F3 TGFB2 
FEV1/FVC (-) rs4328080 (chr1:219,963,088) LYPLAL1/RNU5F-1 SLC30A10* 
FEV1/FVC (FEV1, FVC) rs62126408 (chr2:18,309,132) KCNS3/RDH14 KCNS3 
FVC# (-) rs1430193 (chr2: 56,120,853) EFEMP1 (intron) EFEMP1 
FEV1 (FVC, FEV1/FVC) rs2571445 (chr2:218,683,154) TNS1 (exon) TNS1* 
FEV1/FVC (-) rs10498230 (chr2:229,502,503) SPHKAP/PID1 SPHKAP* 
FVC (FEV1) rs1595029 (chr3: 158,241,767) RSRC1 (intron) RSRC1*, GFM1, MLF1, 
FLJ40475, MFSD1, LXN 
FEV1# (-) rs1344555 (chr3:169,300,219) MECOM (intron) MECOM 
FEV1/FVC (-) rs2045517 (chr4: 89,870,964) FAM13A (intron) FAM13A 
FEV1 (FVC, FEV1/FVC) rs10516526 (chr4:106,688,904) GSTCD (intron) INTS12*, GSTCD*, 
NPNT* 
FEV1/FVC (FEV1, FVC) rs34712979 (chr4:106,819,053) NPNT (intron) NPNT* 
FEV1 rs34480284 (chr4: 106,064,626) LOC101929468/TET2 PPA2 
FEV1/FVC (FEV1) rs138641402 (chr4:145,445,779) GYPA/HHIP-AS1 HHIP* 
FEV1/FVC (-) rs153916 (chr5 95,036,700) SPATA9/RHOBTB3 RHOBTB3*, ARSK, 
SPATA9 
FEV1 (FVC, FEV1/FVC) rs7715901 (chr5:147,856,392) HTR4 (intron) FBXO38, SPINK7 
FEV1/FVC (FEV1) rs1990950 (chr5: 156,920,756) ADAM19 (intron) ADAM19*, NIPAL4, 
CYFIP2, THG1L 
FEV1 (FVC, FEV1/FVC) rs34864796 (chr6:27,459,923) ZNF184/LINC01012 OR2B2* 
FEV1/FVC (FEV1) rs2857595 (chr6:31,568,469) NCR3/AIF1 MICB* 
FEV1/FVC (-) rs2070600 (chr6:32,151,443) AGER (exon) AGER* 
FEV1 (FVC, FEV1/FVC) rs114544105 (chr6:32,635,629) HLA-DQB1/HLA-DQA2 HLA-DQB1*, APOM*, 
RNF5* 
FEV1/FVC (-) rs2768551 (chr6: 109,270,656) ARMC2 (intron) SESN1, ARMC2 
FEV1/FVC (FEV1) rs113096699 (chr6:142,745,883) GPR126 (intron) GPR126* 
FEV1/FVC (-) rs148274477 (chr6:142,838,173) GPR126/LOC153910 GPR126* 
  
FEV1/FVC (-) rs16909859 (chr9: 98,204,792) PTCH1 PTCH1, NEFH 
FEV1/FVC (-) rs803923 (chr9:119,401,650) ASTN2 (intron) ASTN2 
FVC (FEV1) rs10858246 (chr9:139,102,831) QSOX2 (intron) QSOX2*, DNLZ, CARD9 
FEV1/FVC (FEV1) rs7090277 (chr10:12,278,021) CDC123 (intron) CDC123, CAMK1D, 
NUDT5 
FEV1 (FVC, FEV1/FVC) rs2637254 (chr10:78,312,002) C10orf11 (intron) C10orf11 
FVC# (-) rs4237643 (chr11:43,648,368) MIR129-2/HSD17B12 HSD17B12 
FVC# (-) rs2863171 (chr11:45,250,732) PRDM11 (3’ UTR) SYT13 
FVC (FEV1) rs2348418 (chr12:28,689,514) CCDC91 (intron) FLJ35252*, CCDC91, 
PTHLH 
FEV1/FVC (-) rs11172113 (chr12:57,527,283) LRP1 (intron) LRP1*, STAT6, 
TMEM194A, ING2 
FEV1/FVC (-) rs12820313 (chr12:96,255,704) SNRPF (intron) SNRPF, NTN4 
FEV1 (-) rs7155279 (chr14:92,485,881) TRIP11 (intron) ATXN3*, TRIP11, CPSF2,  
FBLN5, NDUFB1 
FEV1# (-) rs117068593 (chr14:93,118,229) RIN3 (exon) RIN3* 
FEV1/FVC (FEV1) rs10851839 (chr15:71,628,370) THSD4 (intron) THSD4*, SENP8 
FEV1/FVC (-) rs12149828 (chr16:10,706,328) EMP2/TEKT5 CLEC16A 
FEV1/FVC (-) rs12447804 (chr16:58,075,282) MMP15 (intron) MMP15*, ZNF319, 
C16orf57, C16orf80, 
CSNK2A2, TEPP 
FEV1/FVC (FEV1) rs3743609 (chr16:75,467,021) 
 
CFDP1 (intron) TMEM170A*, BCAR1*, 
CFDP1*, ADAT1 
FVC (-) rs1079572 (chr16:78,187,138) WWOX (intron) WWOX 
FEV1 (FVC, FEV1/FVC) rs35524223 (chr17:44,192,590) KANSL1 (intron) KANSL1*, MAPT*, 
ARL17B*, ARL17A*, 
LRRC37A4*, NUDT1*, 
LRRC37A*, CRHR1*, 
LRRC37A2*, 
ARHGAP27*, FMNL1*, 
PLEKHM1*, WNT3*, 
NSF*, SPPL2C*, 
TBC1D24, GOSR2,  
EPB41L5, CCDC43,  
DCAKD, SPPL2C 
FEV1 (FVC) rs7218675 (chr17:73,513,185) TSEN54 (intron) CASKIN2*, TSEN54*, 
TSEN54, MRPS7, 
KIAA0195, GRB2, LLGL2, 
NUP85, KIAA0195, 
MIF4GD 
FEV1/FVC (-) rs113473882 (chr19:41,124,155) LTBP4 (intron) LTBP4* 
FEV1/FVC (-) rs2834440 (chr21:35,690,499) LINC00310/KCNE2 KCNE2, LINC00310,  
MRPS6 
 Supplementary Table 16: Gene-based pathway analyses. Summary of gene sets overrepresented in known biological pathways and gene ontology (GO) 
terms. Pathway analysis results for (i) all high-priority genes (n=68) and (ii) analysis including all implicated causal genes (excluding non-high-priority genes at 
the HLA regions, n=234) are presented separately. GO term categories (m= molecular function, b= biological process, c= cellular component) and levels (1 to 5 
with high level GO terms assigned to level 1) are indicated. The effective size is the number of genes present in that respective pathway or GO term. Pathways 
or gene sets represented by only 2 genes from the same association signal have been excluded. Pathways or gene sets which include 2 or more genes implicated 
via the same association signal have been noted. FDR: False discovery rate. 
All high-priority genes (n=68) 
Overrepresented biological pathways 
None at FDR<0.05 
Overrepresented gene ontology terms 
P value FDR Name of GO term (GO term category/level) Genes associated with GO term Total size 
of GO 
geneset 
Notes 
5.42E-05 0.001 SH3 domain binding (m/4) MYPN, ADAM19, BCAR1, ARHGAP27, MAPT 117 
ARHGAP27 and MAPT 
implicated by the same signal 
(rs35524223); and MYPN is a 
novel gene at a novel signal. 
ADAM19 is implicated at both a 
novel and a previously-
reported signal. 
2.43E-04 0.037 fibroblast migration (b/5) TNS1, AGER, MTA2 35 
MTA2 is a novel gene at a novel 
signal 
7.70E-04 0.059 cellular response to misfolded protein (b/5) RNF5, ATXN3 12  
1.06E-03 0.019 protein domain specific binding (m/3) 
MYPN, WNT3, NSF, CARD9, ARHGAP27, MAPT, 
ADAM19, BCAR1 597 
WNT3, NSF, ARHGAP27 and 
MAPT are all implicated by 
rs35524223; and CARD9 and 
MYPN are novel genes at 
different novel signals. 
ADAM19 is implicated at both a 
novel and a previously-
reported signal. 
1.39E-03 0.019 apolipoprotein binding (m/3) LRP1, MAPT 16  
 1.48E-03 0.012 small GTPase binding (m/5) RHOBTB3, FMNL1, RIN3, NSF, SLC6A4 240 
NSF and FMNL1 implicated by 
rs35524223; and SLC6A4 is a 
novel gene at a novel signal 
1.57E-03 0.012 syntaxin-1 binding (m/5) NSF, SLC6A4 17 
SLC6A4 is a novel gene at a 
novel signal 
2.14E-03 0.015 GTPase binding (m/4) RHOBTB3, FMNL1, RIN3, NSF, SLC6A4 261 
NSF and FMNL1 implicated by 
rs35524223; and SLC6A4 is a 
novel gene at a novel signal 
2.40E-03 0.015 actin binding (m/4) SLC6A4, FMNL1, SSH2, ABLIM3, MYPN, TNS1 392 
SSH2 and SLC6A4 implicated by 
rs59835752; and ABLIM3, 
MYPN, and SSH2 and SLC6A4 
are novel genes at three 
different novel signals 
3.87E-03 0.035 protein complex binding (m/3) 
LRP1, SLC6A4, FMNL1, NSF, NPNT, LTBP4, MAPT, 
MTA2, CRHR1 902 
MAPT, FMNL1, CRHR1 and NSF 
are implicated by rs35524223; 
and MTA and SLC6A4 are novel 
genes at different novel signals 
All plausible genes (excluding non-high-priority genes in HLA region, n=234) 
Overrepresented biological pathways 
P value FDR Name of pathway Genes in pathway Total size 
of pathway 
geneset 
Notes 
7.71E-06 0.003 
Signaling events mediated by the Hedgehog 
family CDON, PTCH1, PTHLH, TGFB2, HHIP 23 
CDON is a novel gene at a 
novel signal; and PTHLH is a 
novel gene at a previously-
reported signal 
3.05E-05 0.006 Molecules associated with elastic fibres EFEMP1, TGFB2, LTBP4, MFAP2, FBLN5 30  
6.60E-05 0.008 Elastic fibre formation EFEMP1, TGFB2, LTBP4, MFAP2, FBLN5 35  
1.00E-04 0.010 Ligand-receptor interactions CDON, PTCH1, HHIP 8 
CDON is a novel gene at a 
novel signal 
 Overrepresented gene ontology terms 
P value FDR Name of GO term (GO term category/level) Genes associated with GO term Total size 
of GO 
geneset 
Flags 
6.99E-05 0.029 extracellular matrix organization (b/4) 
HSD17B12, MMP15, TGFB2, CTSK, ADAMTSL4, 
EFEMP1, ITGA1, THSD4, NTN4, NPNT, LTBP4, 
MFAP2, CTSS, LEMD3, FBLN5 388 
ADAMTSL4, CTSS and CTSK 
implicated by the same signal 
(rs6681426) 
7.20E-05 0.019 extracellular structure organization (b/3) 
HSD17B12, MMP15, TGFB2, CTSK, ADAMTSL4, 
EFEMP1, ITGA1, THSD4, NTN4, NPNT, LTBP4, 
MFAP2, CTSS, LEMD3, FBLN5 389 
ADAMTSL4, CTSS and CTSK 
implicated by the same signal 
(rs6681426); LEMD3 and ITGA1 
are novel genes at different 
novel signals 
3.24E-04 0.014 fibronectin binding (m/3) HSD17B12, CTSS, CTSK, MFAP2 28 
CTSS and CTSK implicated by 
the same signal (rs6681426) 
4.23E-04 0.014 hedgehog family protein binding (m/3) PTCH1, HHIP 3  
8.62E-04 0.020 protein domain specific binding (m/3) 
MLF1, MYPN, LLGL2, HPCAL4, STMN3, WNT3, 
EPB41L5, NSF, SLC22A4, SLC22A5, CARD9, GRB2, 
ARHGAP27, MCL1, MAPT, ADAM19, BCAR1 597 
EPB41L5, WNT3, NSF, 
ARHGAP27 and MAPT are all 
implicated by rs35524223; also 
SLC22A4 and SLC22A5 are 
implicated by the same signal 
(rs7713065). GRB2 and LLGL2 
are also implicated by the same 
signal (rs7218675). CARD9, 
HPCAL4, STMN3 and MYPN are 
novel genes at different novel 
signals 
1.22E-03 0.021 protein complex binding (m/3) 
HSD17B12, SLC6A4, ITGA1, MACF1, CTSK, 
MFAP2, CORO6, FMNL1, NEFH, NSF, FBLN5, 
TRAF3IP1, MTA2, LTBP4, CTSS, ING2, LRP1, 
NPNT, GIT1, MAPT, PTCH1, CRHR1 902 
FMNL1, NSF, CRHR1 and MAPT 
implicated by rs35524223; and 
CTSS and CTSK are implicated 
by the same signal (rs6681426). 
NEFH and PTCH1, SLC6A4 and 
GIT1, and ING2 and LRP1 are 
also implicated by the same 
signals (rs16909859, 
rs59835752 and rs11172113 
respectively). MACF1, ITGA1, 
GIT1, CORO6, SLC6A4, MTA2 
and TRAF3IP1 are novel genes 
at different novel signals 
 2.82E-03 0.067 SH3 domain binding (m/4) 
ARHGAP27, GRB2, MYPN, MAPT, ADAM19, 
BCAR1 117 
ARHGAP27 and MAPT 
implicated by the same signal 
(rs35524223); MYPN is a novel 
gene at a novel signal. ADAM19 
is implicated at both a novel 
and a previously-reported 
signal. 
3.18E-03 0.036 organellar small ribosomal subunit (c/5) MRPS7, MRPS6, MRPS21 25  
3.76E-03 0.036 Golgi stack (c/5) 
INPP5E, AP4M1, GOLPH3L, NSF, GOSR1, 
GAL3ST4 124 
GAL3ST4 and AP4M1 
implicated by the same signal 
(rs72615157). GOSR1, GAL3ST4 
and AP4M1 are also novel 
genes at novel signals. INPP5E 
is a high priority gene at a 
novel signal. 
3.98E-03 0.036 MLL1/2 complex (c/5) TAF6, KANSL1, RUVBL1 27 
TAF6 and RUVBL1 are novel 
genes at different novel signals 
5.39E-03 0.036 Golgi cisterna (c/5) AP4M1, GOSR1, GOLPH3L, GAL3ST4, INPP5E 94 
GAL3ST4 and AP4M1 
implicated by the same signal. 
GOSR1, INPP5E, GAL3ST4 and 
AP4M1 are novel genes at 
novel signals.  
 Supplementary Table 17: Results of MAGENTA pathway analysis. Results (P value and FDR) 
presented for analyses run with the HLA region included and with the HLA region excluded. Green shading 
indicates FDR<5% for either analysis. PMF: PANTHER Molecular Functions, PBP: PANTHER Biological 
Processes, PP: PANTHER Pathways, GO: Gene Ontology term, KEGG: Kyoto Encyclopedia of Genes and 
Genomes. 
Database Gene set 
HLA 
included 
P value 
HLA 
included 
FDR 
HLA 
excluded 
P value 
HLA 
excluded 
FDR 
FEV1     
KEGG SYSTEMIC LUPUS ERYTHEMATOSUS 1.60E-04 0.0080 3.97E-03 0.2489 
KEGG ALLOGRAFT REJECTION 8.20E-05 0.0092 7.82E-02 0.5623 
KEGG GRAFT VERSUS HOST DISEASE 2.18E-04 0.0100 0.146 0.4988 
KEGG ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY ARVC 9.00E-04 0.0319 1.90E-03 0.2317 
KEGG ASTHMA 2.10E-03 0.0389 8.14E-02 0.5696 
FEV1/FVC     
PMF Major histocompatibility complex antigen 6.00E-06 0.0005 5.60E-02 0.8659 
GO nucleosome 4.00E-06 0.0012 4.50E-05 0.0487 
KEGG SYSTEMIC LUPUS ERYTHEMATOSUS 1.70E-05 0.0019 1.34E-03 0.1877 
GO antigen processing and presentation of peptide antigen via MHC class 
I 
9.00E-06 0.0019 1.34E-02 0.4215 
PMF Histone 4.30E-05 0.0027 1.85E-04 0.0237 
PBP MHCI-mediated immunity 2.50E-05 0.0030 1.13E-02 0.1534 
KEGG CELL ADHESION MOLECULES CAMS 1.31E-04 0.0118 2.63E-02 0.4948 
KEGG TYPE I DIABETES MELLITUS 4.66E-04 0.0134 0.670 0.9957 
Ingenuity PXR.RXR.Activation 8.00E-04 0.0258 2.00E-03 0.1722 
KEGG GRAFT VERSUS HOST DISEASE 1.22E-03 0.0272 0.644 0.9495 
Ingenuity Interferon.Signaling 2.30E-03 0.0389 5.40E-03 0.0976 
PBP Phagocytosis 1.20E-03 0.0392 3.60E-03 0.1309 
KEGG ALLOGRAFT REJECTION 2.63E-03 0.0407 0.799 1.0000 
PBP Cell communication 5.00E-04 0.0474 1.60E-03 0.1238 
KEGG VIRAL MYOCARDITIS 2.50E-03 0.0475 0.363 0.9522 
KEGG ANTIGEN PROCESSING AND PRESENTATION 2.46E-03 0.0487 0.901 1.0000 
FVC     
PP FAS signaling pathway 3.00E-06 0.0001 8.00E-06 <0.00001 
KEGG SYSTEMIC LUPUS ERYTHEMATOSUS 2.15E-04 0.0278 1.10E-03 0.2039 
Ingenuity Hepatic.Cholestasis 1.10E-03 0.0348 3.50E-03 0.0657 
GO positive regulation of apoptosis 2.80E-05 0.0399 2.40E-05 0.0369 
  
 Supplementary Table 18: Chromatin Mark enrichment. Results of analysis of enrichment for overlap of 
lung function signals with H3K4me1 and H3K4me3 histone marks in 127 tissues/cell types from the 
Roadmap/ENCODE projects. Tables A and B: overlap of H3K4me1 using hypergeometric test and 
GoShifter, respectively. Tables C and D: overlap of H3K4me3 using hypergeometric test and GoShifter, 
respectively. Tissue/cell types that were significant using both the hypergeometric test and GoShifter are in 
bold. 
A) H3K4me1 overlap using hypergeometic test 
 
Tissue/cell type P value FDR 
E083 Fetal Heart <0.001 0.016 
E076 Colon Smooth Muscle <0.001 0.016 
E078 Duodenum Smooth Muscle 0.001 0.024 
E055 Foreskin Fibroblast Primary Cells skin01 0.001 0.031 
E111 Stomach Smooth Muscle 0.003 0.047 
E065 Aorta 0.003 0.047 
E088 Fetal Lung 0.004 0.053 
E126 NHDF-Ad Adult Dermal Fibroblast Primary Cells 0.005 0.053 
E090 Fetal Muscle Leg 0.007 0.070 
E056 Foreskin Fibroblast Primary Cells skin02 0.009 0.087 
E075 Colonic Mucosa 0.010 0.087 
B) H3K4me1 overlap using GoShifter method 
 
Tissue/cell type 
P value 
E072 Brain Inferior Temporal Lobe 0.008 
E088 Fetal Lung 0.017 
E128 NHLF Lung Fibroblast Primary Cells 0.018 
E058 Foreskin Keratinocyte Primary Cells skin03 0.024 
E061 Foreskin Melanocyte Primary Cells skin03 0.030 
E083 Fetal Heart 0.039 
E111 Stomach Smooth Muscle 0.042 
E023 Mesenchymal Stem Cell Derived Adipocyte Cultured Cells 0.046 
E089 Fetal Muscle Trunk 0.046 
 
C) H3K4me3 overlap using hypergeometic test 
 
Tissue/cell type P value FDR 
E065 Aorta 9.30E-05 0.006 
E106 Sigmoid Colon 1.05E-03 0.026 
E126 NHDF-Ad Adult Dermal Fibroblast Primary Cells 1.29E-03 0.026 
E092 Fetal Stomach 1.32E-03 0.026 
E013 hESC Derived CD56+ Mesoderm Cultured Cells 4.68E-03 0.060 
E035 Primary hematopoietic stem cells 4.78E-03 0.060 
E109 Small Intestine 6.58E-03 0.060 
E090 Fetal Muscle Leg 6.61E-03 0.060 
E005 H1 BMP4 Derived Trophoblast Cultured Cells 7.64E-03 0.060 
E062 Primary mononuclear cells from peripheral blood 8.46E-03 0.060 
E086 Fetal Kidney 8.89E-03 0.060 
E026 Bone Marrow Derived Cultured Mesenchymal Stem Cells 9.75E-03 0.060 
E084 Fetal Intestine Large 0.010 0.060 
E029 Primary monocytes from peripheral blood 0.010 0.060 
  
Tissue/cell type P value FDR 
E089 Fetal Muscle Trunk 0.010 0.060 
E031 Primary B cells from cord blood 0.013 0.069 
E085 Fetal Intestine Small 0.015 0.071 
E104 Right Atrium 0.017 0.071 
E046 Primary Natural Killer cells from peripheral blood 0.018 0.071 
E095 Left Ventricle 0.019 0.071 
E116 GM12878 Lymphoblastoid Cell Line 0.019 0.071 
E088 Fetal Lung 0.020 0.071 
E093 Fetal Thymus 0.021 0.071 
E083 Fetal Heart 0.022 0.071 
E037 Primary T helper memory cells from peripheral blood 2 0.022 0.071 
E097 Ovary 0.022 0.071 
E004 H1 BMP4 Derived Mesendoderm Cultured Cells 0.023 0.073 
E078 Duodenum Smooth Muscle 0.024 0.073 
E053 Cortex derived primary cultured neurospheres 0.025 0.076 
E091 Placenta 0.026 0.078 
E122 HUVEC Umbilical Vein Endothelial Cells Cell Line 0.027 0.078 
E075 Colonic Mucosa 0.028 0.078 
E098 Pancreas 0.035 0.088 
E055 Foreskin Fibroblast Primary Cells skin01 0.035 0.088 
E076 Colon Smooth Muscle 0.036 0.088 
E001 ES-I3 Cell Line 0.037 0.089 
E082 Fetal Brain Female 0.038 0.089 
E028 Breast variant Human Mammary Epithelial Cells (vHMEC) 0.040 0.091 
E044 Primary T regulatory cells from peripheral blood 0.044 0.095 
E111 Stomach Smooth Muscle 0.045 0.095 
E121 HSMM cell derived Skeletal Muscle Myotubes Cell Line 0.045 0.095 
E128 NHLF Lung Fibroblast Primary Cells 0.049 0.100 
D) H3K4me3 overlap using GoShifter method 
 
Tissue/cell type P value 
E122 HUVEC Umbilical Vein Endothelial Cells Cell Line 0.010 
E111 Stomach Smooth Muscle 0.025 
E063 Adipose Nuclei 0.035 
E124 Monocytes-CD14+ RO01746 Cell Line 0.041 
 
  
 Supplementary Table 19: Druggability analysis. Genes encoding targets for which there are approved 
drugs and/or clinical candidates in ChEMBL. Indications were ordered by 'Max phase' (i.e. the maximum 
phase a clinical trial has reached). *High-priority genes. Phase 1: Testing of drug on healthy volunteers for 
dose-ranging; Phase 2: Testing of drug on patients to assess efficacy and safety; Phase 3: Testing of drug on 
patients to assess efficacy, effectiveness and safety; and Phase 4: Approval of drug and post-marketing 
surveillance. EFO: Experimental Factor Ontology; MeSH: Medical Subject Headings. 
A) All genes 
Lung function Sentinel SNP 
(trait), position, gene, 
ChEMBL Target ID, name 
Approved drugs 
and clinical 
candidates 
[ChEMBL ID] 
Approved drugs and 
Clinical candidates 
[Name] 
Indications [MeSH/EFO term] (Max phase for indication) 
rs1192404 (FEV1/FVC) 
chr1: 92,068,967 
CDC7 
CHEMBL5443 
Cell division cycle 7-related 
protein kinase 
CHEMBL3544943  BMS-863233 Hematologic Cancer (2) 
CHEMBL3545090  RXDX-103 Cancer (N/A) 
CHEMBL3545321  NMS-1116354 Advanced Solid Tumors (1) 
rs6688537 (FEV1/FVC) 
chr1: 239,850,588 
*CHRM3 
CHEMBL245 
Muscarinic acetylcholine 
receptor M3 
 
CHEMBL14  CARBACHOL GLAUCOMA (4) 
CHEMBL550  PILOCARPINE GLAUCOMA (4), URINARY INCONTINENCE (1) 
CHEMBL1133  OXYBUTYNIN 
CHLORIDE 
HYPERHIDROSIS (4), POLYURIA (4), URINARY INCONTINENCE (4), 
URINARY BLADDER NEUROGENIC (3) 
CHEMBL1184  ACETYLCHOLINE 
CHLORIDE 
GLAUCOMA (4) 
CHEMBL1231  OXYBUTYNIN HYPERHIDROSIS (4), POLYURIA (4), URINARY INCONTINENCE (4), 
URINARY BLADDER NEUROGENIC (3) 
CHEMBL1240  PROPANTHELINE 
BROMIDE 
DIGESTIVE SYSTEM DISEASES (4) 
CHEMBL517712  ATROPINE DIGESTIVE SYSTEM DISEASES (4), PARKINSON'S DISEASE (4), 
PEPTIC ULCER (4), SEASONAL ALLERGIC RHINITIS (4), AMBLYOPIA 
(3), PAIN (3), GLUCOSE INTOLERANCE (1) 
CHEMBL1578  ANISOTROPINE 
METHYLBROMIDE 
Peptic Ulcer (N/A) 
CHEMBL523299  UMECLIDINIUM 
BROMIDE 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (4), ASTHMA (2), 
HYPERHIDROSIS (1) 
CHEMBL1724  MEPENZOLATE 
BROMIDE 
DIGESTIVE SYSTEM DISEASES (4) 
CHEMBL551466  ACLIDINIUM 
BROMIDE 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (4) 
CHEMBL1768  BETHANECHOL 
CHLORIDE 
EOSINOPHILIC ESOPHAGITIS (2), TYPE 2 DIABETES MELLITUS (1) 
CHEMBL1200330  PILOCARPINE 
HYDROCHLORIDE 
GLAUCOMA (4), URINARY INCONTINENCE (1) 
CHEMBL1200347  ISOPROPAMIDE 
IODIDE 
DIGESTIVE SYSTEM DISEASES (4) 
CHEMBL1200473  CYCLOPENTOLATE 
HYDROCHLORIDE 
Retinopathy of Prematurity (N/A) 
CHEMBL1200479  DICYCLOMINE 
HYDROCHLORIDE 
DIGESTIVE SYSTEM DISEASES (4) 
CHEMBL1200604  TROPICAMIDE SIALORRHEA (2) 
CHEMBL1200764  METHACHOLINE 
CHLORIDE 
ASTHMA (4) 
CHEMBL1200771  TRIDIHEXETHYL 
CHLORIDE 
DIGESTIVE SYSTEM DISEASES (4) 
CHEMBL1200803  SOLIFENACIN 
SUCCINATE 
POLYURIA (4), URINARY INCONTINENCE (4) 
CHEMBL1200880  DIPHEMANIL 
METHYLSULFATE 
DIGESTIVE SYSTEM DISEASES (4) 
CHEMBL1200891  OXYPHENCYCLIMINE 
HYDROCHLORIDE 
DIGESTIVE SYSTEM DISEASES (4) 
CHEMBL1200906  OXYPHENONIUM 
BROMIDE 
DIGESTIVE SYSTEM DISEASES (4) 
 Lung function Sentinel SNP 
(trait), position, gene, 
ChEMBL Target ID, name 
Approved drugs 
and clinical 
candidates 
[ChEMBL ID] 
Approved drugs and 
Clinical candidates 
[Name] 
Indications [MeSH/EFO term] (Max phase for indication) 
CHEMBL1200935  DARIFENACIN 
HYDROBROMIDE 
POLYURIA (4), URINARY INCONTINENCE (4) 
CHEMBL1200950  CLIDINIUM BROMIDE DIGESTIVE SYSTEM DISEASES (4) 
CHEMBL1201024  METHSCOPOLAMINE 
BROMIDE 
DIGESTIVE SYSTEM DISEASES (4) 
CHEMBL1201027  GLYCOPYRROLATE 
BROMIDE 
OBSTRUCTIVE LUNG DISEASE (4), CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE (3), DIGESTIVE SYSTEM DISEASES (4), 
ASTHMA (2) 
CHEMBL1201765  FESOTERODINE 
FUMARATE 
POLYURIA (4), URINARY INCONTINENCE (4), NOCTURIA (2) 
CHEMBL1626570  HEXOCYCLIUM 
METHYLSULFATE 
DIGESTIVE SYSTEM DISEASES (4) 
CHEMBL1722209  TOLTERODINE 
TARTRATE 
POLYURIA (4), URINARY INCONTINENCE (4), KIDNEY CALCULI (2) 
CHEMBL2134724  IPRATROPIUM 
BROMIDE HYDRATE 
OBSTRUCTIVE LUNG DISEASE (4), CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE (4), NASAL OBSTRUCTION (4) 
CHEMBL2146146  ATROPINE SULFATE DIGESTIVE SYSTEM DISEASES (4), PARKINSON'S DISEASE (4), 
PEPTIC ULCER (4), SEASONAL ALLERGIC RHINITIS (4), AMBLYOPIA 
(3), PAIN (3), GLUCOSE INTOLERANCE (1) 
CHEMBL2218917  CEVIMELINE 
HYDROCHLORIDE 
Xerostomia (4) 
CHEMBL3084748  TROSPIUM CHLORIDE POLYURIA (4), URINARY INCONTINENCE (4), CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE (1) 
CHEMBL3545181  TIOTROPIUM 
BROMIDE 
ASTHMA (4), CHRONIC OBSTRUCTIVE PULMONARY DISEASE (4), 
CYSTIC FIBROSIS (3) 
CHEMBL1779046  Tarafenacin Overactive Bladder (2) 
CHEMBL3545222  AZD8683 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2) 
rs62126408 (FEV1/FVC -
previous) 
chr2: 18,309,132 
KCNS3 
CHEMBL2362996 
Voltage-gated potassium 
channel 
CHEMBL284348  DALFAMPRIDINE MULTIPLE SCLEROSIS (4), STROKE (3), RENAL INSUFFICIENCY (1) 
CHEMBL1200728  GUANIDINE 
HYDROCHLORIDE 
HEART FAILURE (3) 
rs10515750 (FEV1/FVC) 
chr5: 156,810,072 
ITK 
CHEMBL2959 
Tyrosine-protein kinase 
ITK/TSK 
CHEMBL1201733 PAZOPANIB 
HYDROCHLORIDE 
NEOPLASMS (4), RENAL CELL CARCINOMA (3), OVARIAN 
CARCINOMA (3), SARCOMA (3), NON-SMALL CELL LUNG 
CARCINOMA (2), HEAD AND NECK SQUAMOUS CELL 
CARCINOMA (2), GASTROINTESTINAL STROMAL TUMOR (2), 
LEIOMYOSARCOMA (2), ACUTE MYELOID LEUKEMIA (2), 
LIPOSARCOMA (2), LYMPHEDEMA (2), AGE-RELATED MACULAR 
DEGENERATION (2), PROSTATE ADENOCARCINOMA (2), GASTRIC 
CARCINOMA (2), HEREDITARY HEMORRHAGIC TELANGIECTASIA 
(2), THYROID CARCINOMA (2), VON HIPPEL-LINDAU DISEASE (2), 
CORNEAL NEOVASCULARIZATION (1) 
rs113745635 (FEV1/FVC) 
chr12: 95,554,771 
NDUFA12 
CHEMBL2363065 
Mitochondrial complex I 
(NADH dehydrogenase) 
CHEMBL1703  METFORMIN 
HYDROCHLORIDE 
TYPE I DIABETES MELLITUS (4), TYPE II DIABETES MELLITUS (4), 
FATTY LIVER (4), GESTATIONAL DIABETES (4), GLUCOSE 
INTOLERANCE (4), OBESITY (4), POLYCYSTIC OVARY SYNDROME 
(4), BRAIN NEOPLASMS (3), BREAST CARCINOMA (3), PROSTATIC 
NEOPLASMS (3), ADENOCARCINOMA (2), NON-SMALL CELL 
LUNG CARCINOMA (2), COLORECTAL NEOPLASMS (2), 
ENDOMETRIAL NEOPLASM (2), LUNG NEOPLASMS (2), 
PULMONARY HYPERTENSION (2), MELANOMA (2), MILD 
COGNITIVE IMPAIRMENT (2), PERIODONTITIS (2), RENAL 
INSUFFICIENCY (2), LI-FRAUMENI SYNDROME (1), NON-
ALCOHOLIC FATTY LIVER DISEASE (1), PANCREATIC NEOPLASMS 
(1) 
CHEMBL3545320  ME-344 Solid Tumors (1) 
rs59835752 (FEV1/FVC) 
chr17: 28,265,330 
*SLC6A4 
CHEMBL228 
CHEMBL1113  AMOXAPINE DEPRESSIVE DISORDER (4) 
CHEMBL1118  DESVENLAFAXINE DEPRESSIVE DISORDER (4), FIBROMYALGIA (2) 
CHEMBL1409  FLUVOXAMINE 
MALEATE 
DEPRESSIVE DISORDER (4), OBSESSIVE-COMPULSIVE DISORDER 
(4), AUTISTIC DISORDER (3) 
 Lung function Sentinel SNP 
(trait), position, gene, 
ChEMBL Target ID, name 
Approved drugs 
and clinical 
candidates 
[ChEMBL ID] 
Approved drugs and 
Clinical candidates 
[Name] 
Indications [MeSH/EFO term] (Max phase for indication) 
Serotonin transporter CHEMBL1692  IMIPRAMINE 
HYDROCHLORIDE 
DEPRESSIVE DISORDER (4), GASTROESOPHAGEAL REFLUX (3), 
PAIN (3) 
CHEMBL1708  PAROXETINE 
HYDROCHLORIDE 
ANXIETY (4), DEPRESSIVE DISORDER (4), POST-TRAUMATIC 
STRESS DISORDER (4), PREMATURE EJACULATION (3), HIV 
INFECTION (1) 
CHEMBL1709  SERTRALINE 
HYDROCHLORIDE 
ANXIETY (4), DEPRESSIVE DISORDER (4), POST-TRAUMATIC 
STRESS DISORDER (4), PANIC DISORDER (4), AUTISM (3), INJURY 
(2) 
CHEMBL1200322  ESCITALOPRAM 
OXALATE 
ANXIETY (4), DEPRESSIVE DISORDER (4), OBSESSIVE-
COMPULSIVE DISORDER (4), POST-TRAUMATIC STRESS 
DISORDER (4), BIPOLAR DISORDER (3), CARCINOMA (3), 
PULMONARY HYPERTENSION (3), CANCER (3), BORDERLINE 
PERSONALITY DISORDER (2), COCAINE DEPENDENCE (2), 
HEPATITIS C (2) 
CHEMBL1200328  DULOXETINE 
HYDROCHLORIDE 
ANXIETY (4), DEPRESSIVE DISORDER (4), DIABETIC 
NEPHROPATHY (4), FIBROMYALGIA (4), OSTEOARTHRITIS (4), 
PAIN (4), NEUROPATHY (4), MULTIPLE SCLEROSIS (3), 
OSTEOARTHRITIS OF THE KNEE (3), ALCOHOLISM (2), ATTENTION 
DEFICIT HYPERACTIVITY DISORDER (2), CHRONIC FATIGUE 
SYNDROME (2), NEURALGIA (2) 
CHEMBL1200332  PROTRIPTYLINE 
HYDROCHLORIDE 
DEPRESSIVE DISORDER (4) 
CHEMBL1200492  NEFAZODONE 
HYDROCHLORIDE 
DEPRESSIVE DISORDER (4) 
CHEMBL1200595  CHLORPHENTERMINE 
HYDROCHLORIDE 
Anorexia (N/A) 
CHEMBL1200609  PAROXETINE 
MESYLATE 
ANXIETY (4), DEPRESSIVE DISORDER (4), POST-TRAUMATIC 
STRESS DISORDER (4), PREMATURE EJACULATION (3), HIV 
INFECTION (1) 
CHEMBL1200631  IMIPRAMINE 
PAMOATE 
DEPRESSIVE DISORDER (4), GASTROESOPHAGEAL REFLUX (3), 
PAIN (3) 
CHEMBL1200710  CLOMIPRAMINE 
HYDROCHLORIDE 
ADEPRESSIVE DISORDER (4), PREMATURE EJACULATION (3) 
CHEMBL1200781  CITALOPRAM 
HYDROBROMIDE 
DEPRESSIVE DISORDER (4), AUTISTIC DISORDER (2), COCAINE 
DEPENDENCE (2), STROKE (2), ALCOHOLISM (1), AUTISM 
SPECTRUM DISORDER (1) 
CHEMBL1200798  TRAZODONE 
HYDROCHLORIDE 
DEPRESSIVE DISORDER (4), INSOMNIA (3), ALCOHOLISM (2) 
CHEMBL1200964  AMITRIPTYLINE 
HYDROCHLORIDE 
DEPRESSIVE DISORDER (4), PAIN (4), MIGRAINE DISORDER (3), 
INSOMNIA (3), MOVEMENT DISORDER (2) 
CHEMBL1201066  VENLAFAXINE 
HYDROCHLORIDE 
ANXIETY (4), DEPRESSIVE DISORDER (4), PROSTATE CARCINOMA 
(3), COCAINE DEPENDENCE (2), PAIN (2) 
CHEMBL1201082  FLUOXETINE 
HYDROCHLORIDE 
DEPRESSIVE DISORDER (4), AUTISTIC DISORDER (3), 
GASTROESOPHAGEAL REFLUX (2), OBSESSIVE-COMPULSIVE 
DISORDER (2), STROKE (2) 
CHEMBL1201156  NORTRIPTYLINE 
HYDROCHLORIDE 
DEPRESSIVE DISORDER (4), GASTROESOPHAGEAL REFLUX (3), 
GASTROPARESIS (3), IRRITABLE BOWEL SYNDROME (2), 
PSORIASIS (2), ATOPIC ECZEMA (1) 
CHEMBL1201728  DESVENLAFAXINE 
SUCCINATE 
DEPRESSIVE DISORDER (4), FIBROMYALGIA (2) 
CHEMBL1615374  VILAZODONE 
HYDROCHLORIDE 
ANXIETY (4), DEPRESSIVE DISORDER (4), MARIJUANA 
DEPENDENCE (2), MEMORY IMPAIRMENT (2) 
CHEMBL2096626  MILNACIPRAN 
HYDROCHLORIDE 
DEPRESSIVE DISORDER (4), FIBROMYALGIA (4), PAIN (4), 
IRRITABLE BOWEL SYNDROME (2), NEURALGIA (2) 
CHEMBL2105732  LEVOMILNACIPRAN 
HYDROCHLORIDE 
DEPRESSIVE DISORDER (4) 
CHEMBL2107387  VORTIOXETINE 
HYDROBROMIDE 
DEPRESSIVE DISORDER (4), ANXIETY (3), LIVER DISEASE (1) 
CHEMBL3039565  DESVENLAFAXINE 
FUMARATE 
DEPRESSIVE DISORDER (4), FIBROMYALGIA (2) 
CHEMBL2104986  TEDATIOXETINE DEPRESSIVE DISORDER (2) 
rs35524223 (FEV1 - previous) 
chr17: 44,192,590 
CHEMBL482950  PEXACERFONT Generalized Anxiety Disorder (2), Irritable Bowel Syndrome (2), 
Major Depressive Disorder (1) 
 Lung function Sentinel SNP 
(trait), position, gene, 
ChEMBL Target ID, name 
Approved drugs 
and clinical 
candidates 
[ChEMBL ID] 
Approved drugs and 
Clinical candidates 
[Name] 
Indications [MeSH/EFO term] (Max phase for indication) 
*CRHR1 
CHEMBL1800 
Corticotropin releasing factor 
receptor 1 
CHEMBL291657  SSR125543 Major Depression (2) 
CHEMBL514270  EMICERFONT Irritable Bowel Syndrome (2) 
CHEMBL1287935  VERUCERFONT Post-Traumatic Stress Disorder (2), Alcohol Dependence (2) 
 
B) Genes encoding targets predicted to interact with high-priority gene products 
Lung function 
Sentinel SNP (trait), 
position, high-
priority gene 
Genes encoding targets 
predicted to interact with 
high-priority gene products 
(ChEMBL ID), name 
Approved drugs 
and clinical 
candidates 
[ChEMBL ID] 
Approved drugs 
and Clinical 
candidates 
[Name] 
Indications [MeSH/EFO term] (Max phase 
for indication) 
rs10870202 (FVC) 
chr9: 139,257,411 
*INPP5E 
  
PIK3CD (CHEMBL3130), 
PIK3CA (CHEMBL4005), 
PI3-kinase p110-delta subunit 
  
CHEMBL2216870  IDELALISIB CHRONIC LYMPHOCYTIC LEUKEMIA (3), 
HODGKINS LYMPHOMA (2), NON-HODGKINS 
LYMPHOMA (2), ALLERGIC RHINITIS (1) 
CHEMBL3545397  Acalisib Lymphoid Malignancies (1) 
CHEMBL3545048  AMG-319 Head and Neck cancer squamous cell 
carcinoma (2), Tumors (1) 
CHEMBL3545052  CUDC-907 Multiple Myeloma (1) 
CHEMBL3545112  ME-401 N/A 
CHEMBL3545141  RP-6530 T-Cell Lymphoma (1) 
CHEMBL3545205  INCB-040093 Refractory Hodgkin Lymphoma (2) 
CHEMBL3545247  CAL-263 Allergic Rhinitis (1) 
CHEMBL3545250  GSK-2269557 Chronic Obstructive Pulmonary Disease (2), 
Asthma (1) 
CHEMBL3545267  TGR-1202 Chronic Lymphocytic Leukemia (1) 
rs2509961 
(FEV1) 
Chr11: 62,310,909 
*MTA2 
HDAC3 (CHEMBL1829), 
Histone deacetylase 3 
CHEMBL98  VORINOSTAT CUTANEOUS T-CELL LYMPHOMA (3), BRAIN 
DISEASE (2), HIV-1 INFECTION (2), ACUTE 
MYELOID LEUKEMIA (2), LYMPHOMA (2), 
NEOPLASM (2), SARCOMA (2), BRAIN 
NEOPLASM (1), BREAST CARCINOMA (1), 
PANCREATIC CARCINOMA (1), OVARIAN 
CARCINOMA (1) 
rs35524223 (FEV1 - 
previous) 
chr17:44,192,590 
*KANSL1 
MGA (CHEMBL2074), 
Maltase-glucoamylase 
CHEMBL1561  MIGLITOL TYPE II DIABETES MELLITUS 
CHEMBL1566  ACARBOSE TYPE II DIABETES MELLITUS (4), METABOLIC 
SYNDROME X (3), NON-ALCOHOLIC FATTY 
LIVER DISEASE (2) 
rs6688537 (FEV1/FVC) 
chr1: 239,850,588 
*CHRM3 
  
HCRTR1 (CHEMBL5113), 
Orexin receptor 1 
CHEMBL1272307  SB-649868 Insomnia (2) 
CHEMBL3545367  LEMBOREXANT Driving performance (1) 
rs3743609 (FEV1/FVC 
- previous) 
chr16:75,467,021 
*BCAR1 
  
JAK2 (CHEMBL2971), 
Tyrosine-protein kinase JAK2 
CHEMBL1795071  RUXOLITINIB 
PHOSPHATE 
POLYCYTHEMIA VERA (3), PRIMARY 
MYELOFIBROSIS (3), ALOPECIA AREATA (2), 
BETA-THALASSEMIA (2), BREAST 
CARCINOMA (2), CACHEXIA (2), HODGKINS 
LYMPHOMA (2), MYELOPROLIFERATIVE 
DISORDER (2), METASTATIC PROSTATE 
CANCER (2), PSORIASIS (2), CHRONIC 
LYMPHOCYTIC LEUKEMIA (1) 
CHEMBL603469  LESTAURTINIB Leukemia (2), Psoriasis (2) 
CHEMBL2035187  PACRITINIB Hodgkin Lymphoma (2) 
CHEMBL1231124  AZD-1480 Primary Myelofibrosis (1) 
CHEMBL2107823  GANDOTINIB N/A 
CHEMBL3545215  BMS-911543 Cancer (2) 
CHEMBL3545217  NS-018 Primary Myelofibrosis (2) 
CHEMBL3544997  LS-104 N/A 
CHEMBL3545241  AC-430 Rheumatoid Arthritis (1) 
 Lung function 
Sentinel SNP (trait), 
position, high-
priority gene 
Genes encoding targets 
predicted to interact with 
high-priority gene products 
(ChEMBL ID), name 
Approved drugs 
and clinical 
candidates 
[ChEMBL ID] 
Approved drugs 
and Clinical 
candidates 
[Name] 
Indications [MeSH/EFO term] (Max phase 
for indication) 
CHEMBL3545328  XL-019 Polycythemia Vera (1) 
rs11172113 
(FEV1/FVC - previous) 
chr12: 7,527,283 
*LRP1 
PLAT (CHEMBL1873), 
Tissue-type plasminogen 
activator 
CHEMBL1046  AMINOCAPROIC 
ACID 
HEMORRHAGE (4), CRANIOSYNOSTOSIS (2) 
rs11172113 
(FEV1/FVC - previous) 
chr12:57,527,283 
*LRP1 
  
PDGFRB (CHEMBL1913), 
Platelet-derived growth factor 
receptor beta 
CHEMBL1421  DASATINIB CHRONIC MYELOGENOUS LEUKEMIA (4), 
BREAST CARCINOMA (2), NON-SMALL CELL 
LUNG CARCINOMA (2), POLYCYTHEMIA VERA 
(2), GLIOBLASTOMA (2), CENTRAL NERVOUS 
SYSTEM CANCER (2), SYSTEMIC 
SCLERODERMA (1) 
CHEMBL1642  IMATINIB 
MESYLATE 
GASTROINTESTINAL STROMAL TUMOR (4), 
CHRONIC MYELOGENOUS LEUKEMIA (4), 
PULMONARY HYPERTENSION (3), SARCOMA 
(3), ASTHMA (2), OVARIAN CARCINOMA (2), 
POLYCYTHEMIA VERA (2), CENTRAL 
NERVOUS SYSTEM CANCER (1) 
CHEMBL1200485  SORAFENIB 
TOSYLATE 
HEPATOCELLULAR CARCINOMA (4), RENAL 
CELL CARCINOMA (3), KIDNEY NEOPLASM 
(3), BREAST CARCINOMA (2), PORTAL 
HYPERTENSION (2), KELOID (2), MELANOMA 
(2), OVARIAN CARCINOMA (2), PULMONARY 
HYPERTENSION (1) 
CHEMBL124660  TANDUTINIB Prostate Cancer (2), Glioblastoma (2), Acute 
Myelogenous Leukemia (1) 
rs3743609 (FEV1/FVC 
- previous) 
chr16:75,467,021 
*BCAR1 
SRC (CHEMBL267), 
Tyrosine-protein kinase SRC 
 
CHEMBL24828  VANDETANIB THYROID CARCINOMA (4), Various Cancers 
(3-1) 
CHEMBL288441  BOSUTINIB CHRONIC MYELOGENOUS LEUKEMIA (4), 
GLIOBLASTOMA (2) 
CHEMBL571546  KX2-391 Prostate Cancer (2) 
rs12447804 
(FEV1/FVC - previous) 
 chr16:58,075,282 
*MMP15 
MMP1 (CHEMBL332), MMP8 
(CHEMBL4588), MMP7 
(CHEMBL4073), 
Matrix metalloproteinase-
1,8,7 
  
CHEMBL1200567  DOXYCYCLINE 
HYCLATE 
ACNE (4), BLEPHARITIS (4), INFECTION (4), 
PERIODONTITIS (4), CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE (4), ALZHEIMERS 
DISEASE (3), HEMORRHAGE (3), URETHRITIS 
(3), PRIMARY SYSTEMIC AMYLOIDOSIS (2), 
ABDOMINAL AORTIC ANEURYSM (2), 
COLORECTAL ADENOCARCINOMA (2), 
DIABETIC RETINOPATHY (2), INFLAMMATION 
(2), NEOPLASM OF MATURE B-CELLS (2), 
AGE-RELATED MACULAR DEGENERATION (2), 
MARFAN SYNDROME (2), PAIN (2), PLEURAL 
EFFUSION (2), RHEUMATOID ARTHRITIS (1) 
CHEMBL1200699  DOXYCYCLINE 
HYDRATE 
ACNE (4), BLEPHARITIS (4), INFECTION (4), 
PERIODONTITIS (4), CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE (4), ALZHEIMERS 
DISEASE (3), HEMORRHAGE (3), URETHRITIS 
(3), PRIMARY SYSTEMIC AMYLOIDOSIS (2), 
ABDOMINAL AORTIC ANEURYSM (2), 
COLORECTAL ADENOCARCINOMA (2), 
DIABETIC RETINOPATHY (2), INFLAMMATION 
(2), NEOPLASM OF MATURE B-CELLS (2), 
AGE-RELATED MACULAR DEGENERATION (2), 
MARFAN SYNDROME (2), PAIN (2), PLEURAL 
EFFUSION (2), RHEUMATOID ARTHRITIS (1) 
CHEMBL2364574  DOXYCYCLINE 
CALCIUM 
ACNE (4), BLEPHARITIS (4), INFECTION (4), 
PERIODONTITIS (4), CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE (4), ALZHEIMERS 
DISEASE (3), HEMORRHAGE (3), URETHRITIS 
(3), PRIMARY SYSTEMIC AMYLOIDOSIS (2), 
ABDOMINAL AORTIC ANEURYSM (2), 
COLORECTAL ADENOCARCINOMA (2), 
DIABETIC RETINOPATHY (2), INFLAMMATION 
(2), NEOPLASM OF MATURE B-CELLS (2), 
 Lung function 
Sentinel SNP (trait), 
position, high-
priority gene 
Genes encoding targets 
predicted to interact with 
high-priority gene products 
(ChEMBL ID), name 
Approved drugs 
and clinical 
candidates 
[ChEMBL ID] 
Approved drugs 
and Clinical 
candidates 
[Name] 
Indications [MeSH/EFO term] (Max phase 
for indication) 
AGE-RELATED MACULAR DEGENERATION (2), 
MARFAN SYNDROME (2), PAIN (2), PLEURAL 
EFFUSION (2), RHEUMATOID ARTHRITIS (1) 
 
 Supplementary Table 20: Characteristics of studies contributing to analyses of COPD susceptibility and risk of exacerbation. Summaries are given 
separately for each analysis subgroup (i.e. cases and controls). SD: Standard Deviation. l: litres. 
Study Name 
Case/control 
status 
n total 
n (%) 
femal
e 
Age 
range 
Age, 
mean 
(SD) 
Height 
range (cm) 
Height, 
mean (SD) 
(cm) 
FEV1, mean 
(SD) (l) 
FEV1/FVC
, mean 
(SD) 
FVC, 
mean 
(SD) (l) 
% ever 
smoker
s 
Pack-
years 
range 
Pack-
years, 
mean 
(SD) 
European ancestry 
BioMe-EUR 
  
  
  
COPD case 207 44.9 56-98 74.1 (9.7) 
147.3-
195.6 
169.1 (10) - - - 45.4 - - 
COPD control 1,817 48.3 48-101 70.2 (9.2) 
141.6-
210.8 
169.6 
(10.3) 
- - - 17.3 - - 
Exacerbation case 8 62.5 62-87 77.5 (9.1) 
149.9-
182.9 
166 (12.9) - - - 37.5 - - 
Exacerbation 
control 
199 44.2 56-98 74 (9.8) 
147.3-
195.6 
169.2 
(9.9) 
- - - 45.7 - - 
DiscovEHR * 
  
  
  
COPD case 1,280 36.4 40-92 
70.1 
(10.8) 
99.1-208.3 
168.9 
(10.1) 
1.5(0.62) 
0.55 
(0.12) 
2.7 (0.88) 92.8 - - 
COPD control 13,321 54.6 40-92 
64.5 
(12.7) 
119.4-
203.2 
168 (10.2) 2.7(0.72) 0.8 (0.05) 
3.38 
(0.92) 
48.8 - - 
Exacerbation case 774 33.9 40-92 71 (10.2) 99.1-208.3 
169.2 
(10.2) 
1.44(0.59) 
0.54 
(0.12) 
2.63 
(0.85) 
96.3 - - 
Exacerbation 
control 
472 39.6 40-92 
68.4 
(11.5) 
137.2-
198.1 
168.6 
(10.2) 
1.6(0.64) 
0.57 
(0.12) 
2.81 
(0.93) 
90.0 - - 
              
COPDGene 
  
  
  
COPD case 2,812 44.3 45-81 64.7 (8.2) 
138.9-
195.6 
169.7 
(9.4) 
1.46(0.64) 
0.49 
(0.13) 
2.95 
(0.91) 
100.0 
10-
331.7 
56.3 (28) 
COPD control 2,534 50.7 45-81 59.5 (8.7) 140-200.3 
169.7 
(9.4) 
2.96(0.69) 
0.78 
(0.05) 
3.81 (0.9) 100.0 
10-
172.5 
37.8 
(20.3) 
Exacerbation case 557 44.5 45-81 63.2 (8.5) 
147.9-
195.6 
168.8 
(9.1) 
1.25(0.59) 
0.45 
(0.13) 
2.74 
(0.87) 
100.0 
10-
237.6 
58 (28) 
Exacerbation 
control 
2,255 44.3 45-81 65 (8.1) 138.9-195 
169.9 
(9.5) 
1.51(0.64) 0.5 (0.13) 3 (0.92) 100.0 
10-
331.7 
55.8 (28) 
ECLIPSE 
  
  
  
COPD case 1,736 33.1 40-75 63.7 (7.1) 142-201 169.5 (9) 1.33(0.52) 
0.45 
(0.12) 
3.01 (0.9) 100.0 6-220 
50.4 
(27.4) 
COPD control 176 42.6 40-75 57.5 (9.5) 151-196 
171.7 
(9.7) 
3.27(0.82) 
0.79 
(0.06) 
4.16 
(1.04) 
100.0 10-230 32.2 (25) 
Exacerbation case 278 31.3 40-75 63.8 (7.3) 144-189 
168.4 
(8.5) 
1.14(0.44) 
0.42 
(0.11) 
2.74 
(0.84) 
100.0 10-220 
51.4 
(29.6) 
 Study Name 
Case/control 
status 
n total 
n (%) 
femal
e 
Age 
range 
Age, 
mean 
(SD) 
Height 
range (cm) 
Height, 
mean (SD) 
(cm) 
FEV1, mean 
(SD) (l) 
FEV1/FVC
, mean 
(SD) 
FVC, 
mean 
(SD) (l) 
% ever 
smoker
s 
Pack-
years 
range 
Pack-
years, 
mean 
(SD) 
Exacerbation 
control 
1,458 33.4 40-75 63.7 (7) 142-201 
169.7 
(9.1) 
1.37(0.52) 
0.45 
(0.12) 
3.06 
(0.91) 
100.0 6-205 50.2 (27) 
NETT/NAS 
  
  
  
COPD case 376 35.9 40-85 67.5 (5.8) 
142.7-
190.5 
168.8 
(9.6) 
0.82(0.26) 
0.32 
(0.06) 
2.62 
(0.83) 
100.0 12-260 
66.4 
(30.7) 
COPD control 435 0.0 48-89 69.8 (7.5) 156.7-192 
174.4 
(6.8) 
3.03(0.51) 
0.79 
(0.05) 
3.83 
(0.63) 
100.0 
10-
185.5 
40.7 
(27.8) 
Exacerbation case 87 36.8 40-77 66.7 (5.7) 
144.8-
185.4 
167.9 
(8.6) 
0.77(0.24) 
0.31 
(0.06) 
2.52 
(0.78) 
100.0 
22-
193.5 
71.8 
(36.2) 
Exacerbation 
control 
277 34.7 49-85 67.7 (5.8) 
142.7-
190.5 
169.3 
(9.6) 
0.83(0.26) 
0.32 
(0.06) 
2.66 
(0.85) 
100.0 12-260 
64.3 
(28.8) 
GenKOLS 
  
  
  
COPD case 854 39.8 40-90 
65.5 
(10.1) 
146-197 169.9 (9) 1.57(0.71) 
0.51 
(0.13) 
2.99 
(0.96) 
100.0 3-130 
31.9 
(18.5) 
COPD control 805 49.8 40-88 55.6 (9.7) 151-200 
171.8 
(8.8) 
3.24(0.73) 
0.79 
(0.04) 
4.11 
(0.94) 
100.0 2.5-90 
19.7 
(13.6) 
Exacerbation case 120 45.0 43-89 68.9 (9.5) 148-185 
167.5 
(8.5) 
1.11(0.48) 
0.44 
(0.13) 
2.48 
(0.75) 
100.0 
3.9-
130 
34 (22.7) 
Exacerbation 
control 
734 39.0 
40.4-
90 
64.9 (10) 146-197 170.3 (9) 1.65(0.71) 
0.53 
(0.13) 
3.07 
(0.96) 
100.0 3-125 
31.6 
(17.7) 
Groningen 
  
COPD case 98 50.0 35-81 58.4 (9.4) 154-194 
170.7 
(9.4) 
0.78(0.47) 
0.34 
(0.12) 
2.29 
(1.01) 
94.8 0-90 
31.7 
(17.4) 
COPD control 42 47.6 46-76 60.6 (8.5) 156-196 
172.5 
(8.3) 
1.33(1.11) 
0.81 
(0.08) 
1.61 
(1.26) 
90.5 0-70 
32.3 
(18.8) 
Laval 
  
COPD case 134 43.3 33-81 64.3 (8.4) 142-183 
164.7 
(8.4) 
1.79(0.48) 
0.59 
(0.08) 
3.07 (0.8) 98.5 
0-
157.5 
53.1 
(29.3) 
COPD control 164 49.4 34-80 
60.5 
(10.1) 
145-188 
164.4 
(9.4) 
2.12(0.53) 
0.76 
(0.04) 
2.8 (0.68) 87.2 0-136 
35.4 
(26.5) 
UBC 
  
COPD case 78 38.5 41-84 63 (8.7) 147-195 
170.6 
(10.2) 
1.87(0.67) 
0.57 
(0.12) 
3.23 
(1.02) 
98.6 0-180 
53.6 
(33.8) 
COPD control 126 54.0 25-80 
63.3 
(10.2) 
152-188 
167.1 
(8.4) 
2.65(0.79) 
0.77 
(0.05) 
3.45 
(1.03) 
91.1 0-125 
36.6 
(26.5) 
LHS 
  
Exacerbation case 100 41.0 36-60 49.5 (6.5) 148-198 170 (9.4) 2.57(0.62) 
0.64 
(0.06) 
4.04 
(0.95) 
100.0 10-156 
45.3 
(22.1) 
Exacerbation 
control 
4,002 36.9 35-62 48.5 (6.7) 142-216 
172.1 
(8.9) 
2.78(0.63) 
0.65 
(0.06) 
4.29 
(0.95) 
100.0 0-190 
40.5 
(18.6) 
deCODE COPD 
** 
COPD case 1,964 58.1 40-100 
67.2 
(10.7) 
145-198 
167.9 
(8.9) 
1.46(0.56) 
0.59 
(0.09) 
2.46 
(0.82) 
78.9 
1.7-
124.8 
45.9 (28) 
 Study Name 
Case/control 
status 
n total 
n (%) 
femal
e 
Age 
range 
Age, 
mean 
(SD) 
Height 
range (cm) 
Height, 
mean (SD) 
(cm) 
FEV1, mean 
(SD) (l) 
FEV1/FVC
, mean 
(SD) 
FVC, 
mean 
(SD) (l) 
% ever 
smoker
s 
Pack-
years 
range 
Pack-
years, 
mean 
(SD) 
  
COPD control 
142,26
2 
49.6 40-100 
61.2 
(12.6) 
146-198 
169.1 
(9.2) 
2.53(0.8) 
0.78 
(0.06) 
3.29 
(1.03) 
21.4 
1-
200.6 
30.6 (24) 
UK Biobank 
  
  
  
COPD case 
984 50.1 41-70 61.9 (6.2) 145-191 
168.3 
(8.6) 1.97 (0.47) 
0.64 
(0.06) 3.1 (0.72) 88 
0-
152.75 23 (20.4) 
COPD control 
26561 61 39-70 55.9 (7.9) 139-200 
167.6 
(8.9) 2.91 (0.66) 
0.78 
(0.04) 
3.74 
(0.85) 39.5 0-210 
16.5 
(13.9) 
UK BiLEVE 
COPD case 
9563 46.4 40-70 58.9 (7.2) 136-203 
168.8 
(9.2) 1.84 (0.54) 
0.61 
(0.07) 
3.01 
(0.82) 60.7 
10.5-
301 
41.6 
(20.9) 
COPD control 
27387 50.8 40-70 56.4 (8) 122-201 168.8 (9) 3.1 (0.76) 
0.78 
(0.04) 
3.99 
(0.96) 47.8 
10.125
-180 
31.2 
(15.1) 
UK Biobank 
+ UK BiLEVE 
Exacerbation case 647 47.0 40-70 61 (6.7) 136-193.5 
167.6 
(9.2) 
1.57(0.53) 0.57 (0.1) 2.76 (0.8) 82.1 0-190 45 (23.6) 
Exacerbation 
control 
9,900 47.0 40-70 59.1 (7.2) 138-203 
168.9 
(9.2) 
1.87(0.53) 
0.62 
(0.07) 
3.03 
(0.81) 
62.0 0-301 
38.7 
(21.6) 
Chinese ancestry 
CKB 
  
  
  
COPD case 7,116 48.1 40-79 62 (8.7) 
101.9-
186.4 
156.3 
(8.6) 
1.45(0.66) 
0.72 
(0.14) 
1.98 
(0.75) 
49.7 0-235 
34.4 
(24.2) 
COPD control 20,919 52.1 40-79 56.7 (9.5) 
113.3-
187.3 
158.3 
(8.3) 
2.23(0.64) 
0.83 
(0.08) 
2.71 
(0.82) 
38.8 0-199 
27.8 
(20.9) 
Exacerbation case 5,292 47.2 40-79 61.9 (8.7) 
101.9-
186.4 
156.3 
(8.6) 
1.46(0.68) 
0.74 
(0.13) 
1.93 
(0.74) 
51.5 0-196 
35.1 
(24.2) 
Exacerbation 
control 
1,824 50.6 40-77 62.4 (8.8) 
131.2-
182.3 
156 (8.5) 1.43(0.6) 
0.66 
(0.13) 
2.14 
(0.74) 
44.2 0-235 
31.9 
(23.8) 
 
*Spirometry results for COPD controls presented in the table for DiscovEHR are based only on 1120 individuals with spirometry data available. 
** Spirometry results for COPD controls presented in the table for deCODE COPD are based only on 2502 individuals with spirometry data available. 
 
 Supplementary Table 21: Weights for risk score in UK Biobank.  Weights for each of the 95 variants 
were selected from studies free of winner’s curse bias as follows: weights from UK Biobank were used for 
47 variants not discovered in UK Biobank, weights from a meta-analysis of COPD case-control studies 
(COPDGene, ECLIPSE, NETT/NAS, GenKOLS) were used for a further 41 variants with data available in 
those studies, weights from a meta-analysis of lung resection cohort studies and deCODE 
(lungeQTL+deCODE) were used for a further 4 variants and weights from deCODE were used for variants 
that did not have data in either COPD case-control or lung resection cohort studies but had data available in 
deCODE (3 variants). Given the limited sample sizes available to estimate some of these weights, 9 variants 
had opposite direction of effect on COPD risk to what would be expected given their effect on lung function. 
We assigned a small weight (the smallest positive logOR across variants = 4.97x10
-5
) to all these variants. 
Markername Chromosome Position Risk allele Non-risk allele Study used for weight Beta weight 
rs2284746 1 17,306,675 G C UK Biobank 0.0587 0.985 
rs17513135 1 40,035,686 T C COPD case-control studies 0.0673 1.130 
rs1192404 1 92,068,967 G A COPD case-control studies 0.0555 0.933 
rs12140637 1 92,374,517 T C COPD case-control studies 0.0152 0.255 
rs200154334 1 118,862,070 CAT C COPD case-control studies 0.0215 0.362 
rs6681426 1 150,586,971 A G UK Biobank 0.0156 0.262 
rs993925 1 218,860,068 C T UK Biobank 0.0171 0.286 
rs4328080 1 219,963,088 G A UK Biobank 0.0555 0.932 
rs6688537 1 239,850,588 A C COPD case-control studies 0.0277 0.465 
rs62126408 2 18,309,132 T C UK Biobank 0.1087 1.826 
rs1430193 2 56,120,853 T A UK Biobank 4.97E-05 0.001 
rs2571445 2 218,683,154 A G UK Biobank 0.0865 1.453 
rs10498230 2 229,502,503 C T UK Biobank 0.1024 1.719 
rs61332075 2 239,316,560 G C COPD case-control studies 0.0814 1.367 
rs12477314 2 239,877,148 C T UK Biobank 0.0833 1.400 
rs1529672 3 25,520,582 C A UK Biobank 0.0500 0.840 
rs1458979 3 55,150,677 G A COPD case-control studies 0.0261 0.439 
rs1490265 3 67,452,043 C A COPD case-control studies 0.0064 0.107 
rs2811415 3 127,991,527 G A COPD case-control studies 0.2078 3.490 
rs1595029 3 158,241,767 C A UK Biobank 0.0317 0.533 
rs56341938* 3 168,715,808 G A COPD case-control studies 4.97E-05 0.001 
rs1344555 3 169,300,219 T C UK Biobank 0.0247 0.416 
rs13110699 4 89,815,695 G T COPD case-control studies 0.1933 3.246 
rs2045517 4 89,870,964 T C UK Biobank 0.0782 1.314 
rs2047409* 4 106,137,033 G A lungeQTL+deCODE 4.97E-05 0.001 
rs10516526 4 106,688,904 A G UK Biobank 0.1086 1.824 
rs34712979 4 106,819,053 A G COPD case-control studies 0.1792 3.009 
rs138641402 4 145,445,779 A T UK Biobank 0.1628 2.733 
rs91731 5 33,334,312 A C COPD case-control studies 0.0222 0.372 
rs1551943 5 52,195,033 A G COPD case-control studies 0.1291 2.169 
rs2441026 5 53,444,498 C T COPD case-control studies 0.0211 0.354 
rs153916 5 95,036,700 T C UK Biobank 0.0405 0.680 
rs7713065 5 131,788,334 A C COPD case-control studies 0.0032 0.054 
rs7715901 5 147,856,392 A G UK Biobank 0.1252 2.102 
rs3839234 5 148,596,693 T TG COPD case-control studies 0.0172 0.289 
rs10515750 5 156,810,072 T C COPD case-control studies 0.1836 3.084 
 rs1990950 5 156,920,756 G T UK Biobank 0.0752 1.263 
rs6924424 6 7,801,611 G T UK Biobank 0.0056 0.093 
rs34864796 6 27,459,923 A G UK Biobank 0.1507 2.530 
rs28986170 6 31,556,155 G GAA COPD case-control studies 4.97E-05 0.001 
rs2857595 6 31,568,469 A G UK Biobank 0.1087 1.825 
rs2070600 6 32,151,443 C T UK Biobank 0.1825 3.064 
rs114544105 6 32,635,629 A G lungeQTL+deCODE 0.0575 0.965 
rs114229351 6 32,648,418 C T lungeQTL+deCODE 0.0231 0.389 
rs141651520 6 73,670,095 ATTCTAT A COPD case-control studies 0.0251 0.422 
rs2768551 6 109,270,656 A G UK Biobank 0.0662 1.112 
rs7753012 6 142,745,883 T G UK Biobank 0.1540 2.586 
rs148274477 6 142,838,173 C T UK Biobank 0.2439 4.095 
rs10246303 7 7,286,445 T A COPD case-control studies 0.0444 0.745 
rs72615157 7 99,635,967 G A COPD case-control studies 0.0100 0.168 
rs12698403 7 156,127,246 A G COPD case-control studies 0.0947 1.590 
rs7872188 9 4,124,377 T C COPD case-control studies 0.0254 0.427 
rs16909859 9 98,204,792 A G UK Biobank 0.0618 1.038 
rs803923 9 119,401,650 A G UK Biobank 0.0519 0.871 
rs10858246 9 139,102,831 C G UK Biobank 0.0245 0.411 
rs10870202 9 139,257,411 C T COPD case-control studies 4.97E-05 0.001 
rs7090277 10 12,278,021 T A UK Biobank 0.0995 1.671 
rs3847402 10 30,267,810 A G COPD case-control studies 0.0564 0.947 
rs7095607 10 69,957,350 A G COPD case-control studies 0.0355 0.596 
rs2637254 10 78,312,002 A G UK Biobank 0.0773 1.298 
rs4237643 11 43,648,368 T G UK Biobank 0.0253 0.424 
rs2863171 11 45,250,732 A C UK Biobank 0.0507 0.851 
rs2509961 11 62,310,909 T C COPD case-control studies 0.0168 0.283 
rs145729347* 11 86,442,733 G C deCODE 0.0377 0.633 
rs567508 11 126,008,910 G A COPD case-control studies 0.0081 0.136 
rs2348418 12 28,689,514 C T UK Biobank 0.0201 0.338 
rs11172113 12 57,527,283 T C UK Biobank 0.0386 0.649 
rs1494502 12 65,824,670 A G COPD case-control studies 0.0721 1.211 
rs113745635 12 95,554,771 T C COPD case-control studies 0.0728 1.223 
rs12820313 12 96,255,704 C T UK Biobank 0.0846 1.420 
rs10850377 12 115,201,436 G A UK Biobank 0.0205 0.345 
rs35506 12 115,500,691 T A COPD case-control studies 4.97E-05 0.001 
rs1698268 14 84,309,664 T A COPD case-control studies 0.0139 0.233 
rs7155279 14 92,485,881 G T UK Biobank 0.0594 0.998 
rs117068593 14 93,118,229 C T UK Biobank 0.0443 0.743 
rs72724130 15 41,977,690 T A COPD case-control studies 0.1461 2.454 
rs10851839 15 71,628,370 T A UK Biobank 0.1144 1.921 
rs12591467 15 71,788,387 C T COPD case-control studies 0.0638 1.072 
rs66650179 15 84,261,689 C CA deCODE 0.0387 0.651 
rs12149828 16 10,706,328 A G UK Biobank 0.0675 1.134 
rs12447804 16 58,075,282 T C UK Biobank 0.0274 0.460 
rs3743609 16 75,467,021 C G UK Biobank 0.0704 1.182 
rs1079572 16 78,187,138 A G UK Biobank 0.0026 0.044 
rs59835752 17 28,265,330 TA T deCODE 4.97E-05 0.001 
 rs11658500 17 36,886,828 A G COPD case-control studies 0.0721 1.210 
rs35524223 17 44,192,590 A T lungeQTL+deCODE 0.0080 0.134 
rs6501431 17 68,976,415 C T UK Biobank 4.97E-05 0.001 
rs7218675 17 73,513,185 A C COPD case-control studies 4.97E-05 0.001 
rs113473882 19 41,124,155 T C UK Biobank 0.1620 2.721 
rs6140050 20 6,632,901 C A COPD case-control studies 0.0154 0.258 
rs72448466 20 62,363,640 C CGT COPD case-control studies 0.0371 0.622 
rs2834440 21 35,690,499 G A UK Biobank 0.0691 1.160 
rs11704827 22 18,450,287 A T COPD case-control studies 0.0184 0.310 
rs134041 22 28,056,338 T C UK Biobank 0.0645 1.084 
rs2283847 22 28,181,399 T C COPD case-control studies 0.0329 0.553 
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